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ANALYSIS OF BENZOFURY COMPOUNDS IN BLOOD USING DIFFERENT 
SAMPLE PREPARATION METHODS AND ULTRA FAST LIQUID 
CHROMATOGRAPHY - TANDEM MASS SPECTROMETRY (UFLC-MS/MS) 
 
KATHERINE ELIZABETH DYE  
ABSTRACT 
“Benzo Fury” compounds and derivatives are enactogens similar to 3,4-
methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine 
(MDMA) in various aspects. These compounds are similar in structure to MDMA and 
MDA, as well as, elicit similar effects such as elevated mood, euphoria and 
hallucinations. This similarity in effect increases the potential for abuse as MDMA has 
become less prevalent in some regions as the use of these new psychoactive substances 
(NPSs) has increased. The benzofury compounds are used as legal alternatives to MDMA 
because of their marketing as “not for human consumption”. With the relative ease in 
obtaining NPSs via the Internet, it is possible that these drugs may soon be prevalent in 
the United States.  
The project’s goal was to separate, detect, and quantitate the benzofury 
compounds and derivatives as well as MDA and MDMA in one method of analysis using 
ultra fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS). The project 
also examined which method of sample preparation is more effective for these 
compounds. 
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Six benzofury compounds were researched: 5-(2-aminopropyl)benzofuran) (5-
APB), 6-(2-aminopropyl)benzofuran) (6-APB), 5-(2-aminopropyl)-2,3-
dihydrobenzofuran (5-APDB), 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB), 1-
(benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB) and 1-(benzofuran-6-yl)-N-
methylpropan-2-amine (6-MAPB) as well as MDMA and MDA. These drugs were 
analyzed in blood. A liquid-liquid extraction (LLE) method and solid phase extraction 
(SPE) method were examined to determine which would be better for the separation, 
detection and quantitation of the benzofury compounds. For the development of the 
overall method, accuracy, precision, calibration curve, carryover, limit of detection, limit 
of quantitation, analyte stability, and recovery were examined.  
The accuracy of the methods examined was greater than + 20%. For most 
analytes, the precision within-run and between-run did not exceed 20%, regardless of the 
sample preparation method used. A weighting of 1/x was applied to the calibration curve 
regardless of sample preparation method utilized. The carryover was less than 2% with 
the SPE method having less carryover (0.02% to 0.50%) than the LLE method (0.05% to 
1.56%). 
The limit of quantitation was determined to be greater than 10 ng/mL. While this 
was unexpected, the limit of detection calculations determined that this was correct. 
Using the LLE method in combination with the UFLC-MS/MS method developed, the 
limit of detection was determined to be at least 9.98 ng/mL. Compared to the LLE 
method, the SPE limit of detection was lower and calculated to be 3.75 ng/mL.  
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The percent recovery was examined for each of the analytes. It was determined 
that the SPE was capable of recovering 80% or more of the benzofury compounds and 
derivatives regardless of the concentration level. The LLE was not as successful in the 
recovering the benzofury compounds, the best recovery occurred at the 200 ng/mL level 
with only 65% or less recovered. Analyte stability exhibited a general decrease with 
variation prior to day 7 and then remains relatively stable until day 14.  
It was anticipated that the quantitation of the drugs might be complicated due to 
the similarity in structure between the isomers as well as the similarity of structure 
between all of the compounds. While this may still be the case, the difficult separation 
resulted in a re-evaluation and alterations to the UFLC-MS/MS method to correct for 
these issues. With the change in the UFLC-MS/MS method, further method optimization 
is required to achieve the appropriate accuracy and limit of quantitation.  It was found 
that the best combination of sample preparation and detection of the benzofury 
compounds and derivatives is to use SPE followed by an UFLC-MS/MS method.  
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1. INTRODUCTION 
 New psychoactive substances (NPSs) are a component of the international drug 
issue and are defined by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) as “synthetic or naturally occurring substances that are not controlled under 
international law, and often produced with the intention of mimicking the effects of 
controlled drugs”1. New psychoactive substances are also referred to as ‘research 
chemicals’, ‘designer drugs’ or ‘legal highs’2. These compounds are designed to imitate 
effects of illicit or controlled substances that are prohibited by legislation and law.1,2  
The new psychoactive substances have different chemical structures from their 
illicit counterparts but produce similar desired effects. Many of these compounds are 
synthesized in clandestine laboratories and sold in a way to circumvent legislation.3 
However, not all of the new structures were designed for illicit drug use. Some of these 
compounds were explored as potential pharmaceuticals, but subsequently were used 
illicitly.4,5 The evaluation of these compounds by academic or pharmaceutical researchers 
was with the intent of creating medications that would give a desired effect such as 
hallucinations or empathy while reducing the associated negative effects of the illicit 
substance such as addiction or harmful physiological effects. Monte et al. explored 
analogues of 3,4-methylenedioxyamphetamine (MDA) and 3,4-
methylenedioxymethamphetamine (MDMA) for use in psychotherapy5 following 
research into the use of MDMA as a method of treating post-traumatic stress disorder 
(PTSD)4. These alternative structures were designed to produce the same effect as 
MDMA (hallucinations and feelings of empathy) while reducing adverse effects such as 
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serotonin neurotoxicity.5 However, it is not always possible to remove all negative 
effects; as such, in addition to their own unique adverse effects(s), many of the analogues 
have similar harmful effects as the illicit drug after which they are modeled.6 An 
unintended outcome of research such as Monte et al. has been a rise in the published 
information and number of analogues specifically designed to elicit similar effects to 
MDMA that can potentially bypass legislation.  
Variations in chemical structures can make the identification and analysis 
challenging. It is difficult to obtain information regarding NPSs due to the almost 
constant changes and alterations of the structures. Most of the information obtained is 
collected from self-reported surveys, drug monitoring systems, and case reports.2 All of 
these methods rely on cooperative and honest users, which pose a number of issues. Not 
all users are honest about their drug habits or are unaware of the specific substance being 
used. Researchers and scientists are examining alternative methods to collect information 
about drug abuse in localized areas using analysis instead of self-reporting data. Archer et 
al. analyzed urine samples collected from “twelve four-bay standalone public urinals” in 
the city of Westminster in England7. This experiment was entirely anonymous in that no 
data was collected regarding the individuals that used the urinals. Archer et al. were able 
to examine the type, number, and metabolites of drugs being used as well as any potential 
cutting agents that may be added to the drugs. The researchers concluded that this method 
has the “potential to detect the use of NPS and other recreational drugs” and can help 
determine “time-trends in NPS use and use of new NPS” as well as “identify 
geographical trends”7. The analysis of collected urine from urinals allows individuals to 
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remain anonymous while providing scientists a more honest survey of drugs being abused 
by individuals in a given area and potentially eliminate some of the errors that arise with 
self-reporting data and surveys. 
There are many different classes of NPSs. Classification can be based on 
psychotropic effects that users experience such as stimulants, enactogens, or 
hallucinogens.3 The NPS can also be classified based on the chemical family such as 
phenethylamines, amphetamines, cathinones, piperazines, pipradrols/piperidines, 
aminoindanes, benzofurans, and tryptamines. Regardless of the classification, NPSs have 
become a global problem. There were 81 new NPSs identified in Europe in 2013 by the 
European Union (EU) Early Warning System.1 To date, the addition of these newly 
identified compounds increased the total number of substances monitored to 3501. The 
drastic increase in the number of NPSs is compounded by the additional burden of 
performing and submitting formal risk assessments for at least six more drugs between 
2013 and early 2014. In 2008, EMCDDA developed a guideline for how to complete an 
official risk assessment for a new substance or drug.8 The risk assessment must examine 
specific considerations and aspects of the illicit substance as outlined in the guideline. 
These considerations include similarity of use and abuse to known substances, 
therapeutic use, addiction potential, effects produced as well as public health and social 
concerns, organized crime affiliations and potential control measures and consequences. 
All of these substances and assessments are monitored and completed by the EU Early 
Warning System, which has the potential to become overburdened by the number of 
substances if they are not already.1   
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Many of the NPSs are manufactured in clandestine laboratories9 or in makeshift 
laboratories in homes of users or suppliers. The sale of NPSs occurs on the Internet as 
well as in “specialized shops known as ‘head shops’”10. Regardless of where the drugs 
are purchased, the NPSs are purposely mislabeled or misbranded to state that the NPS is 
‘not for human consumption’3,11. Many of these drugs use the disguise of ‘research 
chemicals’, ‘bath salts’, ‘plant food’, or ‘fish food’ to allow the selling and purchasing of 
the illicit substance with a perceived lower risk of legal action. These drugs are sold 
without any safety data12, ingredient lists or concentration. Their availability may lead 
individuals to believe that these drugs are safe and acceptable since they appear to be sold 
legally. This notion is incorrect since many of these drugs have not been tested on 
humans.13 
Researchers have begun to evaluate the labeling of various NPSs to determine 
their accuracy. Baron et al. purchased and analyzed seven different types of NPSs to 
determine the active ingredient present.13,14 Out of the seven NPSs purchased, six did not 
contain the advertised drug. Instead, the most active ingredient was caffeine. Five of the 
samples contained the controlled drugs benzylpiperazine (BZP) and 1-[3-
(Trifluoromethyl)phenyl]piperazine (3-TFMPP) with caffeine.13 The researchers utilized 
Fourier Transform Infrared (FTIR) spectroscopy and gas chromatography-mass 
spectrometry (GCMS) for the analysis followed by another experiment examining 
microcrystal testing.13,14 The authors found that the microcrystal test analysis resulted in 
the same conclusion as the FTIR and GCMS analysis, therefore, these NPSs can be 
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identified as incorrect or mislabeled using a presumptive test as well as in confirmatory 
testing.  
The false advertising of these compounds presents a number of problems. 
Individuals may believe the package labeling or advertising but this may be inaccurate 
and lead to serious health issues. When the advertising and labeling fails to match the 
substance inside, an increase in risk is posed to the user and an inexperienced or “first-
time” user may experience toxic and potentially fatal poisonings after one dose.15 With 
the ease that many of the NPSs can be purchased, this could become a widespread issue. 
It is in this regard that NPSs present a complex problem that “affects both the health and 
security of citizens worldwide”16. 
  This project focuses on a new group of NPSs known as the benzofurans or 
‘Benzo Fury’ compounds. The benzofury compounds are abused because they produce an 
effect similar to MDMA or Ecstasy. Since MDMA is illegal and more difficult to obtain, 
many individuals have started using these compounds as a replacement. Drug availability 
is a key factor in the willingness of users to try different substances.1 Since MDMA is a 
scheduled drug in many European countries, the EMCDDA has reported a decline or 
stable level of its abuse from 2007 to 2012 in young adult users (ages 15 to 34), with the 
exception being Bulgaria.1 
 
1.1 Methylenedioxymethamphetamine (MDMA) 
3,4-Methylenedioxymethamphetamine (MDMA) or Ecstasy is a synthetic 
amphetamine that has obtained various levels of popularity over the last four decades.17 
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Structurally, MDMA is similar to amphetamine and mescaline, giving it the stimulant and 
hallucinogenic properties that are desired by users.18 Since MDMA has both stimulant 
and hallucinogenic properties, it has been classified as an ‘enactogen’. The term 
‘enactogen’ was first described and published by Dr. David E. Nichols based on the use 
of MDMA in psychology which allowed individuals to “access and deal with repressed 
painful emotional issues”19. Many still feel that MDMA can still be used in 
psychotherapy which has led to research in MDMA and structural analogues4,5,19. The use 
of MDMA in psychotherapy sessions is one of the various settings that it is used in 
medicinally. However, it is most commonly associated with ‘raves’, dance clubs, and 
concerts, and is also used illicitly in smaller social gatherings.18  
Merck first discovered MDMA in Darmstadt, Germany around 1912.20 It was 
initially believed that Merck discovered MDMA as an appetite suppressant, but 
Freudenmann et al. discovered that it was “a precursor of a new chemical pathway which 
was patented in order to avoid an existing patent for the synthesis of the clotting agent 
hydrastinine”20. Despite its early discovery, MDMA was not widely used as a 
recreational drug until the 1970s.21 Since MDMA is an analogue of amphetamine and 
mescaline, it was not regulated under the Controlled Substances Act of 1970. It wasn’t 
until the Anti-Drug Abuse Act of 1986 that MDMA and other designer drugs were 
regulated and made illicit. The term ‘designer drugs’ was used in 1980s to refer to drugs 
that were made in clandestine laboratories from products that could be purchased over-
the-counter, resulting in drugs that were structurally different than illicit drugs. Ecstasy or 
MDMA is still referred to as a designer drug.21,22  
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There are many reported effects of MDMA. The desired psychological effects of 
MDMA include euphoria, altered perception, relaxation, hallucinations, as well as the 
feeling of closeness with other individuals and sexual arousal.18,19 However, some 
individuals will experience negative psychological effects such as anxiety, panic attacks, 
paranoia, flashbacks, rage, depression and suicidal ideation.17 The physiological effects 
of MDMA include tachycardia, hypertension, altered body temperature, nausea, 
vomiting, mydriasis, bruxism, dry mouth, and seizures.17,23 Despite the fact that many 
individual perceive MDMA as a relatively safe drug, it can have fatal complications.22 
Fatalities with this drug are associated with acute renal failure, disseminated intravascular 
coagulation, rhabdomyolysis, heart failure, convulsions, hemorrhage, serotonin 
syndrome, hepatic failure, and cardiovascular collapse.17,23  
The psychological effects are a result of interactions between MDMA and the 
neurotransmitters serotonin and dopamine. These effects seem to be caused by MDMA’s 
ability to affect the “release and reuptake inhibition of brain monoamines, particularly 
serotonin and dopamine”18. It is considered a selective serotonergic neurotoxin as well as 
dopamine neurotoxin.19,22 However, the long-term effects of altering the serotonin and 
dopamine in the brain have yet to be studied. While there have been animal studies, these 
studies are not necessarily indicative of the effects of MDMA in the human brain. There 
is a possibility that the neurotoxicity could be reversible in humans.19  
Ecstasy and MDMA is sold illicitly in various different forms such as pills, 
tablets, and powders. Regardless of its form, MDMA is present and administered as a 
mixture of two enantiomers.22 The enantiomers have different pharmacodynamics, 
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specifically, the S enantiomer is more potent and neurotoxic than the R enantiomer. Since 
these enantiomers have different effects on the body, they also have different 
pharmacokinetics. 
The use and possession of MDMA has been illegal in United States since 1985.24 
It is a Schedule I drug of the Controlled Substance Act meaning that it has no medical use 
and a high potential for abuse.21 This scheduling has not prevented the use of MDMA. In 
the recent years, MDMA has continued to be used at concerts and raves but under a new 
pseudonym, “Molly”.25  “Molly” is short for “molecule” and has been known to contain 
pure MDMA as well as other illicit drugs.25 “Molly” is perceived as safer than Ecstasy 
since it is pure, with no adulterants or diluents, and limited addictive qualities25. With the 
rise of “Molly”, MDMA made a resurgence, leading to a larger number of individuals 
using MDMA. According to the National Forensic Laboratory Information System 
(NFLIS) 2013 mid-year report, MDMA has been on the decline since 2009 but it did 
have an increase in prevalence in casework between 2001 and 2009.26 As of the 2013 
report, MDMA was still listed in the top 25 most frequently identified drugs but with 
only 2,423 cases identified nationwide.26 Since law enforcement and legislation has 
become aware of “Molly”, many structural analogues have started to appear that imitate 
the desired effects of hallucinations, euphoria and closeness. These new psychoactive 
substances include synthetic cathinones (bath salts) as well as benzofurans.25 These 
structural analogues are a concern for many individuals because they have the potential to 
exhibit similar effects, specifically adverse effects, as MDMA and potentially produce 
new effects that are unknown to both users and scientists alike.27   
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1.2 Methylenedioxyamphetamine (MDA) 
 3,4-Methylenedioxyamphetamine (MDA) is well known metabolite of 
methylenedioxyamphetamine derivatives, specifically MDMA and MDEA 
(methylenedioxyethylamphetamine).22 Both MDMA and MDEA are metabolized by N-
demethylation to the metabolite MDA.28 However, MDA poses an additional problem. It 
is not only a metabolite but is a designer drug in its own right. It is also known as the 
“love drug”, “Love” or “tenamfetamine”19,28–30. While MDA is no longer popular to use 
by itself, it has been found in Ecstasy pills and with methamphetamine.28  
 A single dose of MDA contains both R and S enantiomers, similar to MDMA.31 
The R isomer is more potent and produces effects similar to lysergic acid diethylamide 
(LSD), specifically hallucinations.24 The S isomer produces effects similar to 
amphetamines, specifically the stimulant effects.24 Since MDA is typically taken as a 
mixture of both enantiomers, an individual will experience both the stimulant and the 
hallucinogenic effects. It is due to that experience that MDA is classified as a 
hallucinogenic amphetamine.29  
It is known as the “love drug” because MDA increases “emotional sensitivity and 
empathy”19. Hallucinations can be experienced with its use, most likely due to the similar 
mechanism of action shared by MDA and LSD.29 Since MDMA and MDA are both 
synthesized from sassafras oil and MDA is a metabolite of MDMA, it is not surprising 
that they share similar effects. Both are considered methylenedioxyamphetamine 
derivatives and both are considered enactogens due to their effects on humans.22 Like 
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MDMA, MDA effects the serotonin and dopamine systems in the brain.22 Both have long 
term risks of serotonin neurotoxcity.22,30  
The increased potency and longer half-life of MDA may be why it is used as an 
adulterant to MDMA.28 Also, there may be a perception that MDA is safer than MDMA 
since the synthesis of MDA is less involved and utilizes chemicals that are easy to obtain 
compared to MDMA. However, it has been hypothesized that “an equivalent dose of 
MDA has the potential to be more harmful than MDMA due to the longer duration of 
action and potential higher potency”28.   
 Like MDMA, MDA is classified as a Schedule I controlled substance in the 
United States.24 As with MDMA, MDA was examined for potential medicinal 
purposes.24,31 It was first discovered in 1910 by German chemists and has been examined 
as a “truth serum”, incapacitating agent, and cough suppressant. It was sold as an appetite 
suppressant in 1961. This may be why MDMA was thought to be an appetite suppressant 
due to its similarity to MDA.20 Like MDMA, MDA was used in psychotherapy since it 
also “increased self-awareness accompanied by elevated sensory intensity” and feelings 
of empathy24. Due to the desired feeling of empathy and hallucinations, this led to MDA 
being abused and thus its scheduling and control. Since then, newer drugs have been 
designed to emulate this effect in attempts to circumvent legislative control.   
 
1.3 Benzofury compounds 
Due to the increased regulation and control of MDA and MDMA, alternative 
drugs have been synthesized. Initially, the synthesis was used for research and 
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pharmaceuticals, not illicit use. MDMA and MDA were examined to determine their use 
in psychotherapy. While there is still currently some research into this area today, 
researchers decided to make structural analogues of MDMA and MDA to circumvent the 
control and restriction regarding these drugs. The structural analogues would allow 
psychiatrists, doctors and patients to use MDMA and MDA legally for medicinal 
purposes. Monte et al. were the first to synthesize 5-(2-aminopropyl)-2,3-
dihydrobenzofuran (5-APDB) and 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB).5 
While it isn’t clear how these structures were altered to create the popular benzofurans 
today, it is important to understand that the creation and alteration of these substances 
had an altruistic nature. 
Regardless of how these drugs were created, they are MDMA and MDA 
analogues. The most prevalent analogues are 5-(2-aminopropyl)benzofuran (5-APB) and 
6-(2-aminopropyl)benzofuran (6-APB).15 Both 5-APB and 6-APB have been packaged 
and sold as “BENZOFURY” or “Benzo Fury”, which is where they (and their 
derivatives) get their name. Both 5-APB and 6-APB are MDA analogues due to the 
similarity in structure.9,15,32–34 The methylenedioxy ring of MDA has been replaced with a 
benzofuran ring. Not only are 5-APB and 6-APB analogues of MDA, but they are also 
structural isomers.35 There are many different structural isomers of APB such as 2-APB, 
4-APB, and 7-APB along with the popular 5-APB and 6-APB. The 2-, 4-, and 7-APB 
isomers are considered to be impurities or byproducts of the 5-APB and 6-APB 
synthesis.4,15,36  
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These drugs are can be purchased as a powder as well as tablets or pills. The 
tablets or pills may be referred to as pellets. The “Benzo Fury” drugs sold in head shop 
are typically tablets or pills. The quantities for these forms range from 100 milligrams 
(mg) to 100 grams (g).32  
The common route of administration for 5-APB and 6-APB is oral.9 There are 
anecdotal reports of individuals snorting or insufflating the powder but it does not seem 
to be the preferred route of administration.9 There are also reports of dissolving 6-APB 
powder in liquids for direct ingestion as well as rectal administration.32  
The onset of action occurs within a half hour to one and half hours, depending on 
the dose.15 There are three general ranges for dosing: the threshold dose is between 30 
and 50 mg, the normal dose is between 50 and 100 mg, and a heavy dose is considered to 
be more than 100 mg. The time to peak effects is approximately two to three hours. Both 
5-APB and 6-APB have been described as having a similar  “come-up” as MDMA but 
somewhat stronger. The “come-down” from 5-APB and 6-APB is more gradual with the 
potential to have effects up to fourteen hours or longer after the initial dose.15 The decline 
is gradual and has been described as “unpleasant” by users of 6-APB that lasts for a few 
days with a “feeling of anxiety that can last up to 5 days after use”32. 
Many animal studies have been conducted to determine the effects of 5-APB and 
6-APB on the body. While these animal studies are not perfect models for the human 
body, they have indicated possible effects from the use of 5-APB and 6-APB. Dawson et 
al. examined the effects of 5-APB on rats and found that 5-APB reacts with dopamine.35 
This interaction allows 5-APB to bind to the dopamine transporter, potentially blocking 
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the reuptake of dopamine and increasing the amount of basal dopamine. This study also 
found that 5-APB is an agonist with serotonin receptors 5HT2A (5-hydroxytryptamine2A) 
and 5HT2B in rats.  The interaction of 5-APB and these two receptors may lead to 
cardiotoxicity, specifically valvulopathy, if the usage is long term.35  
Iverson et al. also examined the effect of 5-APB and 6-APB on human 
receptors.12 This study found that 5-APB had a high affinity for serotonin receptor 5HT2B 
and was a potent full agonist of this receptor. As for 6-APB, it is a potent full agonist for 
5HT2B and has a high affinity for adrenoreceptor α2C, meaning that it interacts with 
norepinephrine. This study may be more representative of the actual effects of these 
drugs on the body since he examined these drugs using cloned human receptors.12 
Regardless of the study, it appears that 5-APB and 6-APB can have interactions with 
dopamine, serotonin and norepinephrine. 
These interactions with various receptors and neurotransmitters is how 5-APB and 
6-APB get their effects. These effects are similar to MDA because 5-APB and 6-APB are 
similar structurally to MDA. Many of these effects are based upon user reports due to the 
limitations in human research. The desired effects from the use of these compounds 
include elevated mood, visual and tactile stimulation, euphoria, an appreciation for 
music, as well as auditory and visual hallucinations.15 Some adverse effects include 
“bruxism, nystagmus, headache, nausea, vomiting, diarrhoea, increase in heart rate, blood 
pressure and body temperature”15. Psychologically, users report feelings of “depression, 
anxiety, panic attacks, insomnia and severe paranoid symptoms”9. Some users of 6-APB 
have reported “palpitations, hot flushes, headache, paranoia, anxiety, and visual and 
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auditory hallucinations”32.  However, some of these reports indicate that 6-APB was 
taken in conjunction with other drugs so it is unclear which drug may have caused some 
of these effects.  
There are also effects related to cardiotoxicity or cardiovascular toxicity of use. 
Since both 5-APB and 6-APB are NPSs, these compounds have been found in mislabeled 
packaging. According to Baron et al., one of the seven NPS purchased was labeled as 
“Benzo Fury” but contained BZP, TMFPP and caffeine.13,14 The mislabeling can lead 
individuals to use the substance believing it is 5 or 6-APB but it is in fact another 
compound. There is also a possibility that 5- or 6-APB could be used in another 
mislabeled NPS as well.  
Due to the increase in number of users and deaths from use, many countries have 
started to demand regulation of 5-APB and 6-APB. Due to the structural difference from 
MDA, 5-APB and 6-APB are not included in the regulation and control of 
phenethylamines substances.15 There are legislative requirements for each new compound 
that is found in each country. In 2013, Professor Iversen wrote a letter to the United 
Kingdom’s Home Secretary requesting that 5-APB and 6-APB be scheduled under the 
Misuse of Drugs Regulations as a Schedule I drug.37 The Misuse of Drugs Regulation is 
the United Kingdom’s equivalent to the Controlled Substances Act in the United States. 
In this report, he included all of the research that has been conducted on 5-APB and 6-
APB regarding its lack of safety, potential for abuse and lack of medicinal purposes.37   
The request was not without reason. There were many deaths in the United 
Kingdom linked to 5-APB or 6-APB use.9,10,15,32,38 Some of these intoxications or deaths 
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involved individuals consuming 5/6-APB and other drugs such as: cannabis (both 
marijuana and synthetic JWH-122)32, 3-methyl-N-methylcathinone (3-MMC)15, 5-(2-
aminopropyl)indole (5-IT)10, and methoxetamine38. There have also been deaths reported 
with the use of 6-APB in the United Kingdom and Sweden.37  
The request also included all of the current research regarding 5-APB and 6-APB. 
This research is examining methods of detection, pharmacology, background, 
toxicology/deaths, as well as, discussing new compounds. Some of these new compounds 
are benzofury derivatives. 
  
1.4 Benzofury derivatives 
 Due to the regulation of 5-APB and 6-APB, many users are searching for 
alternatives to 5-APB and 6-APB. Some of the new benzofury compounds or derivatives 
include: 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB), 6-(2-aminopropyl)-2,3-
dihydrobenzofuran (6-APDB), N-methyl-5-(2-aminopropyl)benzofuran (5-MAPB) and 
N-methyl-6-(2-aminopropyl)benzofuran (6-MAPB). The 5-APDB and 6-APDB are 
structurally similar to MDA but the benzofuran ring is saturated with hydrogen. The 5-
MAPB and 6-MAPB are more structurally similar to MDMA since they both have the 
addition of a methyl group on the nitrogen. 
 Since the use of APDB and MAPB is a recent development, research 
investigating these compounds is lacking. Welter et al. have examined metabolites as 
well as methods of detection for APB and MAPB.33,34 One component of the research 
involved dosing rats with MAPB or APB and evaluating the metabolism of these 
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compounds. Welter et al. determined that 6-APB is the N-demethyl metabolite of 6-
MAPB.34 According to their research, similar metabolic profiles may also apply to the 5-
APB and 5-MAPB isomers.  
 Since most of the benzofury compounds are isomers, research on analytical 
separation of isomers has been conducted. Initially, separation of the 5 and 6 isomer was 
difficult. If researchers were unable to distinguish the 5 isomer from the 6 isomer, the 
toxicology report would state 5/6-APB.38 Since then, many researchers have examined 
methods of separating the isomers. Taschwer et al. examined separating enantiomers 
using capillary electrophoresis.11 In this study, they were able to separate the enantiomers 
in twenty minutes. This separation also allowed the researchers to conclude that there is a 
clear distinction between the isomer as well as the derivatives.11 Welter et al. were able to 
differentiate and separate between the APB and MAPB using GCMS.34 The separation 
was completed by preparing a solution containing 5-APB, 5-MAPB, 6-APB and 6-
MAPB and analyzing the run on GCMS post derivatization. Welter et al. concluded that 
the elution order was 5-APB, 6-APB, 5-MAPB and 6-MAPB.34  
 Regarding the neurotransmitter interaction of the derivatives, this research is still 
on going. Recently, Rickli et al. determined that 5-APDB inhibited serotonin uptake more 
potently compared to MDMA.6 Also that 5-APDB and 6-APDB have noradrenergic and 
serotonergic activities and less potent dopamine transporter activity. Rickli et al. 
concluded based on their rat studies that 5-APDB and 6-APDB produce similar effects to 
MDMA.6 At this time, there are no studies examining the effects of MAPB on rats.  
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1.5 Prevalence 
The prevalence of the benzofury compounds is difficult to determine. Due to the 
novelty of these drugs, many questionnaires do not incorporate these compounds into 
user surveys. Rather, these surveys ask general questions on NPSs without listing each 
individual drug. Instead, there is focus on the classification of NPSs such as 
phenethylamines, cathinones, and cannabinoids. This makes it is difficult to determine 
how much of the phenethylamines category statistics apply directly to benzofury 
compounds.  
Despite this, there is still some information regarding the introduction of these 
compounds. King produced a table in his article regarding when each new 
phenethylamines was first reported to the EMCDDA.4 According to this information, 5-
APB was first reported to the EMCDDA in 2010, followed by 6-APB in 2011. As for the 
derivatives, they were first reported to the EMCDDA later: APDBs were identified in 
2012 and MAPBs were identified in 2013.4 Considering that the derivatives were first 
reported to EMCDDA in 2012, it is not surprising that there is a lack of information 
regarding their prevalence.  
There is some information regarding where these compounds are identified.  
The United Nations Office on Drugs and Crime (UNODC) issued a Novel Psychoactive 
Report in March 2013.39 In this report, 5-ABP was identified in Bulgaria, Spain, Finland, 
Great Britain, Italy and the Netherlands during 2012. It also stated that 6-APB was 
identified in Australia, Canada, Spain, Finland, Netherlands and Norway during 2012.39  
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In the Netherlands, Hondebrink et al. examined NPSs in the drug market and 
poison control centers.2 The research found that 6-APB appeared for the first time in the 
Netherlands during 2011. In 2012, 5-APB was first identified and in 2013, 5-APDB and 
6-APDB were first identified. Overall, Hondebrink et al. concluded that there was an 
increase in percentage of NPSs and believe that this was linked to an unstable 
amphetamine and Ecstasy market during 2008 and 2009. They believe that the instability 
of the market resulted in the use of NPSs in place of amphetamine and ecstasy in powders 
and tablets sold during this time. Hondebrink et al. also discussed that the market has 
stabilized so the presence of NPSs in Ecstasy and amphetamine drugs has also 
decreased.2  
 In the United Kingdom and Ireland, there was an epidemic leading to the 
scheduling of the benzofury compounds. Like other NPSs, the benzofury compounds are 
not restricted to Europe and can be purchased via the Internet, making their use 
widespread. A benzofury derivative (5-APDB) was identified in samples purchased on 
the Internet by Uchiyama et al. in Japan.40 The unknown pale orange liquid was 
purchased between January and August 2013. The liquid was analyzed using LCMS and 
GCMS and found to contain 5-APDB. This was an early instance of benzofury 
compounds being identified in Japan.40 
 While this is a majority of the information on the benzofury compounds, there is a 
lot of information regarding prevalence and usage of MDMA, Ecstasy, amphetamine type 
stimulants, as well as, MDMA-like compounds. As previously discussed, Archer et al. 
examined pooled urinals located throughout central London. The researcher were able to 
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identify MDMA and its metabolites in 11 out of 12 different public urinals.7 While the 
usage of MDMA or Ecstasy is on the decline in England, it is still being used in London. 
According to the European Drug Report produced by the EMCDDA, there were 
3,979,497 Ecstasy tablets seized across the Europe Union (EU) during 2013.1 There were 
11,281 seizures throughout the EU. However, it should be noted that this value is a fifth 
of the value of seized tablets during 2005. The prevalence estimates for lifetime of 
Ecstasy users in the EU is approximately 3.1% with 1.0% of young adults using within 
the last year (12 months). The EMCDDA report also discusses that a majority of the 
production of Ecstasy during 2013 was located in Belgium and the Netherlands. Also 
noted in this report was that stimulant use is higher in southeastern Europe, specifically in 
Bulgaria, Greece, Romania and Turkey.1 
 According to the UNODC’s World Drug Report 2014, there are approximately 
between 9.4 and 28.2 million users of Ecstasy globally.41 The average global prevalence 
of Ecstasy is 0.4%. While Ecstasy declined globally between 2010 and 2012, some 
regions are still above the global average. The Oceania region, which consists of 
Australia and New Zealand, has the highest percentage at 2.9%. In North America, the 
percentage is 0.9%.41 
 In the United States, MDMA and Ecstasy has had a similar trend compared to 
Europe. According to the National Forensic Laboratory Information System (NFLIS), 
Ecstasy has had varying levels of prevalence in casework.26 There was decrease between 
2001 and 2003, an increase between 2003 and 2009 and then a decline since 2009. 
However, MDMA is still in the top 25 most commonly identified drugs in casework. In 
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2013, there were 2,423 national cases that contained MDMA. The report also noted that 
MDMA is the fourth most reported phenethylamine.26  
 Ecstasy or MDMA has declined in popularity in youths in the United States.42 
Monitoring The Future (MTF) conducts an annual survey of eighth, tenth, and twelfth 
graders across the United States. Overall, the trends of lifetime use prevalence have 
decreased with the prevalence in 2014 being 3.5%. In regards to annual use prevalence, 
there was a similar downward trend with the value for 2014 being 2.2%. For the 30-day 
prevalence of use category, only 0.8% of high school students answered that they had 
used. However, twelfth graders tend to have higher percentages for all of the prevalence 
categories compared to eighth graders.42  
 Regarding the availability of drugs, it appears that both eighth graders and twelfth 
graders believe that is “fairly” or “very easy” to get MDMA.42 Approximately 10% of 
eighth graders felt that it was “easy” to get MDMA, which is an increase from 2013. 
Approximately 36% of twelfth graders felt that it was “fairly easy” to get MDMA, which 
was an increase of 1.1% from 2013. It should be noted that MTF altered questions about 
MDMA to include the term “Molly”. Previously, MDMA was referred to as MDMA or 
Ecstasy. With the addition of Molly, MTF thought that it might be able to reach a larger 
group of students that may not realize that MDMA and “Molly” are the same drug. 
However, MTF stated that it did not observe a change in responses regarding MDMA.42 
 Due to the increase in regulations and restrictions of MDMA due to “Molly” and 
resurgence of Ecstasy, this may lead to a lack of availability of MDMA. When there is a 
lack of availability of a drug, this can lead to the possibility of other drugs that exhibit 
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similar effects filling the role of these drugs. Since these benzofury compounds are very 
similar to MDMA and MDA, it is possible that restrictions on MDMA and MDA will 
result in users moving to these benzofury compounds. To complicate this issue, 
mislabeling of NPSs can also result in the rapid spread of drugs. According to a 
EMCDDA and Europol Joint Report on 5-(2-aminopropyl)indole, there were 116 
branded packets of “BENZO FURY” seized from a headshop in the UK.43 When analysis 
was performed, no benzofury compounds were identified. Instead, another NPS (5-(2-
aminopropyl)indole) was identified.43 If this is occurring with other NPSs, it is always 
possible that this could occur with the benzofury compounds.  
 
1.6 Structures 
 
Figure 1: Structures of MDA, APB and APDB6. 
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Figure 2: Structure of MDMA and MAPB44–46. 
 
1.7 Hypothesis 
The purpose of the project is to establish a method for the analysis of benzofury 
compounds in blood based on extraction methods currently used in forensic laboratories. 
The extraction analysis would allow for the determination of the best method for 
recovering low traces of the benzofury drugs from toxicology samples. This method 
examined the possibility of separating out the structural isomers to allow for the 
combined analysis of these compounds.  
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2. EXPERIMENTAL DESIGN 
 
2.1 Solid Phase Extraction 
  Solid phase extraction (SPE) is a sample preparation method commonly used in 
forensic toxicology. According to Wille et al., “the objective of SPE is to remove 
interfering compounds and to concentrate analytes with good recovery and reproducible 
results”47. To achieve this objective, SPE relies on the packing material in the extraction 
column. The packing materials can include silica, polymers or carbon particles. These 
materials can be modified to create different surface chemistry, thus making the SPE 
more selective for specific analytes of interest.48  
The four steps in a typical SPE process are conditioning the column, adding the 
sample, washing the column, and eluting the desired analytes from the column.47–49 The 
silica column is the material that retains the desired analytes while the undesired 
components are removed by utilizing a series of wash steps. The cartridge is conditioned 
to rehydrate the silica beads to optimize the interactions between the sample analytes and 
the beads. After the column has been conditioned, the sample is added. The column then 
undergoes a series of washes to remove the undesired cellular components from the 
analyte. These undesired components are removed because their presence may negatively 
affect the chromatography. After the washes, the analytes are eluted from the extraction 
column into a test tube or directly into a vial for analysis. If the eluate is allowed to dry, it 
will be reconstituted with an appropriate solvent or solvent mixture for the method of 
analysis.  
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Solid phase extraction is a very efficient method for sample preparation and is 
commonly used in laboratories. The ability to automate SPE has led to its prevalence, 
which allows analysts to run samples in large groups (also known as batches) and 
minimizes the use of solvents. However, SPE does have some disadvantages. These 
disadvantages include variability between cartridge batches as well as complications 
standardizing vacuuming and drying techniques utilized.47,49 Both of these disadvantages 
will affect reproducibility of results.  
 
2.2 Liquid-Liquid Extraction  
  Liquid-liquid extraction (LLE) is sample preparation method that utilizes the 
differences in solvent polarity. This method of extraction is based on using immiscible 
liquids to force an analyte from one liquid into another. Various chemical properties can 
be manipulated to facilitate LLE such as pH, ionization and polarity. This extraction 
technique is also known as an organic extraction because it utilizes organic or nonpolar 
chemicals. Typically, the biological sample is added to a test tube along with a “water-
immiscible solvent”48. The mixture is given time to settle or centrifuged to separate into 
the two layers: organic layer and aqueous layer. Depending on the analyte, it can be in 
either phase. The affinity or polarity of the analyte of interest dictates the phase in which 
it will be found. If the analyte is non-polar or has an affinity for non-polar, it will be 
found in the organic phase and that phase should be sampled. The phase with the desired 
analyte is removed and added to a vial for analysis or a test tube for evaporation followed 
by reconstitution.  
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This method is used because it has been stated that it is “the cleanest sample 
preparation and can be applied to analytes that dissolve readily in water-immiscible 
solvent”48. However, it cannot be automated and may not be the preferred method due to 
the amount of high-purity solvent required, labor involved and the time-consuming nature 
of the method.47,48 This method may also result in incomplete separation or “emulsions” 
which can complicate analysis.47 There is a potential for more toxic waste produced using 
this method, which can be costly to dispose of properly. This method is often used for 
“urgent screening purposes”, specifically when the analysis is not focused on one analyte 
but rather the group of analytes present.47  
 
2.3 Ultra Fast Liquid Chromatography  
  Chromatography is the process of separating compounds. Liquid chromatography 
(LC) is the separation of compounds by changing the polarity of a liquid, the 
concentration of a liquid or the pressure of each liquid. The separation of compounds in 
LC occurs based on the interaction between the analyte, the mobile phase(s) and the 
stationary phase (column).50 The method of LC separation is similar to the SPE method. 
The sample is introduced onto the column. The column is typically packed with silica 
beads with a certain chemical groups that will interact with the desired compounds. The 
individual components of the sample will be removed from the column depending the 
component’s affinity for the mobile phase or the stationary phase. The individual 
components will flow into the detector.  
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There are three basic composition classes for the LC separations: normal phase, 
reverse phase and chiral separation.50 Normal phase utilizes a polar stationary phase and a 
nonpolar mobile phase. The reverse phase consists of a nonpolar stationary phase and 
polar mobile phase. Chiral separation utilizes a stationary phase that has “optically active 
materials” to separate out stereoisomers (compounds that have the same molecular 
formula but differ in their three dimensional orientations).50 Regardless, interactions 
between the mobile phase and stationary phase must be considered. Any interactions such 
as degradation of stationary phase can cause issues with the separation of compounds.   
 
2.4 Electrospray Ionization  
 Electrospray ionization (ESI) is the method of ionizing compounds separated 
from the LC before sending them to the mass spectrometer.51 There are various different 
methods of ionizing compounds with ESI considered a soft ionization technique. It is the 
softest technique because of the method used to obtain the precursor ion. The mobile 
phase from the LC is ionized when it enters the ESI interface. This interaction causes the 
mobile phase to become aerosol or gas, which produces charged droplets.  These charged 
droplets burst due to columbic explosion (based on the net charge of the droplet). The 
ions formed from this spray are charged and can be detected using positive or negative 
ionization mode. The positive ionization mode creates ions that are the molecular weight 
of the ion plus a hydrogen [M+H]. The negative ionization creates ions that are the 
molecular weight minus a hydrogen [M-H]. The creation of the ions occurs at 
atmospheric pressure, not in a vacuum. These ions then pass into the mass spectrometer.51  
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2.5 Mass Spectrometry 
  Mass spectrometry (MS) is fragmentation of compounds to help determine 
chemical structure. A mass spectrometer ionizes the compounds separated from the LC 
and separates, detects and measures according to the mass-to-charge ratios (m/z).51 The 
separation of ions occurs in the mass analyzer. There are two common types of mass 
analyzers: the quadrupole and the ion trap. A quadrupole consists of four parallel poles 
configured in a square.52 The quadrupoles utilize direct current (DC) and radio frequency 
(Rf) to separate ions. Two diagonal poles will utilize DC and the other two will utilize Rf 
frequencies. The poles will alternate back and forth between DC and Rf. This will only 
allow the desired ions to pass through to the detector. Once through the quadrupole, the 
ions are detected, amplified and recorded.51  
 
2.6 Tandem Mass Spectrometry (MS/MS)  
  Tandem mass spectrometry (MS/MS or MSn) refers to a method of utilizing 
multiple mass spectrometers to monitor multiple transitions and fragmentations.51 
Tandem MS “improves the selectivity, specificity and/or sensitivity of detection” 
compared to single MS methods.51 Tandem MS can be tandem in time or tandem in 
space. A triple quadrupole mass spectrometer is tandem in time. A triple quadrupole mass 
spectrometer utilizes three quadrupoles at the same time (tandem in time). Each 
quadrupole does not function in the same way with the first quadrupole (Q1) acting as a 
mass filter in that it scans for the precursor ion [M+H+] for positive ionization mode and 
sends that into the next quadrupole. This quadrupole, known as Q2, takes the parent ion 
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from Q1 and fragments it. The second quadrupole (Q2) is also known as the collision 
cell. The collision cell fragments the precursor ion by collision-induced dissociation 
(CID) or collisionally-activated dissociation (CAD).51 Both CID and CAD utilize a 
neutral gas (nitrogen) to fragment the precursor ions and send all of the fragments into 
the third quadrupole (Q3). In Q3, the fragments are scanned and sorted before entering 
into the detector. Once in the detector, the ions are detected, amplified, and recorded.51   
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3. MATERIALS/METHODS 
 
 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-
methylenedioxyamphetamine (MDA), 5-(2-aminopropyl)benzofuran (5-APB), 6-(1-
aminopropyl)benzofuran (6-APB) and their deuterated internal standards (d5) were 
purchased from Cerilliant Corporation (Round Rock, TX). The drugs and internal 
standards were received in a methanol solution at a concentration of one milligram per 
milliliter (mg/mL). The benzofury derivatives, 5-(2-aminopropyl)-2,3-dihydrobenzofuran 
(5-APDB), 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB), 1-(benzofuran-5-yl)-N-
methylpropan-2-amine (5-MAPB), and 1-(benzofuran-6-yl)-N-methylpropan-2-amine (6-
MAPB), were purchased from Cayman Chemical Company (Ann Arbor, MI). The 
derivatives were purchased in salt form at a weight of one milligram (mg). The 
derivatives were dissolved in one milliliter of methanol to create the standard of 1 
mg/mL. A table with all the compounds and lot or batch numbers can be found in Table 
A of Appendix A.  
All extraction and chromatography chemicals were purchased through Thermo 
Fisher Scientific (Waltham, MA) and were of ACS Plus certified, HPLC grade or higher. 
All vials and disposable culture tubes were purchased from Thermo Fisher Scientific. 
Solid phase extraction was performed on a solid phase extraction positive pressure 
manifold (PPM) purchased from United Chemical Technologies, Incorporated (UCT) 
(Bristol, PA). Clean-Screen® CSDAU206 SPE cartridges were purchased from UCT. The 
certified drug free whole blood was purchased frozen from UTAK Laboratories, 
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Incorporated (Valencia, CA). Water was purified using a Synergy UV water system from 
EMD Millipore/Merck (Darmstadt, Germany) and will be referred to as millipore water. 
 The analysis was performed on a Shimadzu Prominence ultra fast liquid 
chromatography system from Shimadzu Corporation (Kyoto, Japan). The mass 
spectrometer was a 4000QTrap from Sciex (Framingham, MA). The software used for 
the validations and analysis was Analyst® (version 1.6.2) and MultiQuant™3.0 (version 
3.05373.0) both purchased from Sciex. 
 
3.1 Reagent Preparation 
  For the solid phase extraction sample preparation, phosphate buffer was prepared 
by weighing out 0.168 grams (g) of disodium phosphate (Na2HPO4) and 1.214 g sodium 
dihydrogen phosphate (NaH2PO4-H2O), dissolved in 80 milliliters (mL) of millipore 
water. The solution was diluted to 100 mL with millipore water and mixed. The pH was 
checked using an Oakton pH 700 meter (purchased from Thermo Fisher Scientific) to 
confirm the pH was between 5.9 and 6.1. The adjusted phosphate buffer was stored in a 
glass container in the refrigerator with a stability of six months. A 0.1 normality (N) 
solution of hydrochloric (HCl) acid was prepared by adding 0.840 mL of concentrated 
HCl to a 100 mL glass container with 10 mL of millipore water. The HCl acid solution 
was diluted to 100 mL with millipore water. The 0.1 N solution of HCl is stable for one 
year at room temperature. The base elution solvent was a solution of methylene chloride 
(77%), isopropyl alcohol (20%) and ammonium hydroxide (3%). A 100 mL volumetric 
flask was used to create the base elution solvent. Isopropanol (20 mL) was added to the 
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flask, followed by 3 mL of ammonium hydroxide and mixed well. The mixture was 
diluted to 100 mL with methylene chloride. The base elution solvent is stable for one 
month at room temperature.   
For the liquid-liquid extraction sample preparation, 0.5 N solution of sodium 
hydroxide was prepared by dissolving 1.996 g of sodium hydroxide in 100 mL of 
millipore water.  
The mobile phases for the LC were 2 mM ammonium formate buffer with 0.2% 
formic acid as mobile phase A and acetonitrile with 0.1% formic acid as mobile phase B. 
The 2 mM ammonium formate buffer was prepared by dissolving 0.126 g ammonium 
formate in 800 mL of millipore water. The mixture was diluted to 1 L with millipore 
water and 2 mL of formic acid was added. The acetonitrile was poured into a 1 L bottle 
and 1 mL of formic acid was added to create mobile phase B. 
 
3.2 Calibration Curve 
For quantitation, a calibration curve was designed. The calibration curve is based 
on the calibration curve used in the Tarrant County Medical Examiner’s Office Procedure 
for Sympathomimetic Amines and Cocaine.53 Seven points of reference were used along 
with a high quality control (QC), a low QC, a negative with internal standards 
(designated as negative), and a negative with no internal standards (designated double 
blank). The calibration curve was extracted for each analytical run. The same curve 
design (as displayed in Table 1) was used for both methods of sample preparation. Two 
different stock solutions were used to create this curve, similar to the stock solutions used 
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in reference procedure.53 All points in the calibration curve received the 1-ug/mL 
internals standard stock solution, 30 uL for the SPE method and 20 uL for the LLE 
method. 
The QCs were from a different stock solution than the calibrators. While both 
came from the same standard lot received, the separate stock solutions were made for the 
calibrators and the QC to mimic the process that would typically occur during method 
validation. Typically, the QC controls should be from a different lot number than the 
calibrators. This was not possible due to the rarity of the compounds examined.  
Table 1. Calibration curve for quantitation. 
Aliquot of 1 ug/mL Stock 
Solution (μL) 
Blood (μL) Final Concentration 
(ng/mL) 
200  100 2000 
160 100 1600 High QC 
100 100 1000 
50 100 500 
20 100 200 
Aliquot of 100 ng/mL Stock 
Solution (μL) 
Blood (μL) Final Concentration 
(ng/mL) 
100 100 100 
60 100 60 Low QC 
50 100 50 
20 100 20 
 
3.3 Solid Phase Extraction 
 The solid phase extraction (SPE) method is the sample preparation for 
sympathomimetic amines, cocaine/cocaine metabolites and other analytes.53 For each 
sample, 100 microliters (ul) of sample was added to a test tube. Phosphate buffer (1 mL) 
and the internal standard (30 uL) at a concentration of 1 ug/mL were added to each 
sample and vortexed. The cartridges were placed on the UCT SPE PPM and conditioned 
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with 1 mL of methanol followed by 1 mL of phosphate buffer. Once the phosphate buffer 
flowed through the cartridges without assistance, the contents of each sample tube was 
added to a cartridge and allowed to pass through without assistance. Once the sample was 
sufficiently embedded in the silica packing material, the cartridge was sequentially 
washed with 1 mL of millipore water, 1 mL of HCl, and 1 mL of methanol. After the 
addition of the reagents, the washes were pushed through the cartridges at a pressure of 5 
pounds per square inch (psi). Following the addition of the methanol, the silica packing 
material was allowed to dry under positive pressure (25 psi) for 5 minutes before elution. 
Two milliliters of the base elution solvent were added to each column and allowed to 
flow freely from the column into the appropriate labeled elution tube. The eluted samples 
were evaporated on a Fisher Scientific Isotemp heating block on low heat setting at level 
10 or approximately 90°C. Once completely dry, the samples were reconstituted with one 
milliliter of 2mM ammonium formate buffer (mobile phase A), vortexed, and transferred 
to the LC vial for analysis. 
 
3.4 Liquid-Liquid Extraction 
  The liquid-liquid extraction is the procedure for the compound Levetiracetam. In 
a glass test tube, 100 uL of sample and 20 uL of the internal standard were added. 
Millipore water (200 uL) was added to the tube followed by 50 uL of 0.1 N sodium 
hydroxide solution then by 2 mL of chloroform. The tubes were capped, vortexed and 
centrifuged at 1500 revolutions per minute (rpm) for 5 minutes. The tubes were removed 
and the bottom layer (chloroform layer) was transferred to another test tube. The test 
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tubes were placed on the Fisher Scientific Isotemp heat block on low heat setting at level 
10 (~90°C) until dry. The samples were reconstituted in 1 mL of 2 mM ammonium 
formate buffer (mobile phase A), vortexed, and transferred to the LC vial for analysis.  
 
3.5 MS/MS Compound Optimization  
Compounds were optimized using procedures provided by Sciex.54–56 Each 
compound was diluted to a 10 nanograms per milliliter (ng/mL) concentration in a 50:50 
mixture of water and methanol. The dilution was added to a syringe and inserted directly 
into the mass spectrometer using a kd Scientific Legato 100 infuse only syringe pump 
(Holliston, MA). The 10-ng/mL dilution was optimized at a flow rate of 10 uL/min. The 
first part of the optimization involved examining the precursor ion in the first quadrupole 
(Q1). The Q1 optimization was done to confirm the presence of the precursor ion and to 
confirm that the isotope peak was the correct size. Once this was confirmed, the 
declustering potential (DP) was determined.  
The second part of the optimization involved identifying the product ions. The 
publications regarding the benzofury compounds’ precursor, product and quantitation 
ions are limited or instrument specific.15,33,34,36,57 This limitation led to the automated 
compound optimization tool within the software to identify the best product ions. For 
some compounds, a manual method was used to examine the potential intensity, which 
allowed for the selection of the quantitative and the qualitative ions. The automated 
optimization process selected three peaks with the highest intensity to use for the 
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procedure. A table with all of the transitions for each compound can be found in 
Appendix A (Table B). 
After the ions were selected, optimization continued to determine the collision 
energy and the cell exit potential. This same method was used for all compounds as well 
as the internal standards.   
The next step was to optimize the ion source for the entire method. Only one 
compound was needed to optimize the ion source for the entire method since the ion 
source will remain the same for all compounds in the method. One compound dilution of 
10 ng/mL was added to the syringe. The syringe was inserted into a T-junction that 
connected the liquid chromatograph and mass spectrometer. The first source parameter 
optimized was the probe position, which was optimized by monitoring the intensity of the 
compound while changing the depth and position in front of the orifice. Once that was 
determined and recorded, the other source parameters were optimized. The source 
parameters were optimized similar to the probe position in that they were altered and the 
intensity was monitored. The other source parameters include: curtain gas, collision gas, 
ionspray voltage, temperature, ion source gas 1, ion source gas 2, interface heater.  
 
3.6 UFLC-MS/MS Conditions 
The final conditions for the UFLC were 2 mM ammonium formate buffer with 
0.2% formic acid as mobile phase A and acetonitrile with 0.1% formic acid as mobile 
phase B. The column was the Kinetex F5 100A 2.6 u 50 mm by 3 mm (Phenomenex, 
Torrance, CA). A SecurityGuard ULTRA Holder with a SecurityGuard Cartridge 
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UHPLC F5 for 3.00 mm protected the Kinetex 2.5 F5 100A column and was purchased 
through Phenomenex. The flow rate was set to 0.500 milliliters per minute (mL/min). The 
injection volume was set to 10 uL. The final conditions for the ions source for the 
MS/MS are shown in Table 2. 
Table 2. Parameters for the ion source.  
Ion Source Parameter Value 
Curtain Gas 10 
Collision Gas Medium 
IonSpray Voltage 5000 
Temperature 500 
Ion Source Gas 1 70 
Ion Source Gas 2 30 
Interface Heater On 
 
 
3.7 Accuracy and Precision  
The accuracy (also known as bias) and precision experiment followed the 
guidelines listed in the Scientific Working Group for forensic toxicologists (SWGTOX) 
Method Validation Guidelines.58 For this experiment, three different samples were 
created and stored in amber glass vials. The blood was added to the vial, followed by the 
appropriate amount of standards in methanol to create samples at three different 
concentrations: 60, 770 and 1600 ng/mL. To create the 1600 ng/mL sample, 2.8 mL of 2 
ug/mL standard solution was added to 3.5 mL of blood. The 770 ng/mL required 2.695 
mL of the 1 ug/mL standard solution added to 3.5 mL of blood. The 60 ng/mL required 
2.1 mL of the 100 ng/mL standard solution added to 3.5 mL of blood. The volume was 
created to accommodate the five replicates over three different days using the two 
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different extraction methods. These samples were sampled and extracted along with a 
fresh calibration curve each time.  
 
3.8 Calibration Curve and Carryover  
The calibration curve and carryover experiment followed the guidelines listed in 
the Scientific Working Group for forensic toxicologists (SWGTOX) Method Validation 
Guidelines.58 A calibration curve was extracted five different times and examined to 
determine the weighting of the system. To determine the amount of carryover, a double 
blank (blank matrix sample) was analyzed after the highest calibrator (2000 ng/mL) to 
determine if there was any carryover between a high concentration sample and the double 
blank.  
 
3.9 Limit of Detection and Limit of Quantitation 
The limit of detection and limit of quantitation experiment followed the 
guidelines listed in the Scientific Working Group for forensic toxicologists (SWGTOX) 
Method Validation Guidelines.58 The limit of detection was determined by examining 
five calibrations curves. These calibration curves are the same ones from the calibration 
curve experiment detailed in Section 3.9. The limit of quantitation was determined by 
extracting matrices spiked at low concentrations outside the calibration curve (1, 5 and 10 
ng/mL). These concentrations were extracted in duplicate and analyzed to determine the 
lowest value that could be quantitated by examining the bias and precision at those levels.  
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3.10 Stability 
The stability study was based on a method that Peters proposed.59 Blood is added 
to twelve amber glass vials and spiked at either 50 ng/mL or 200 ng/mL with the 
appropriate stock solution. For the 50-ng/mL samples, 2 mL of the 100-ng/mL stock 
solution was added to 4 mL of blood. For the 200-ng/mL samples, 800 uL of the 1-ug/mL 
stock solution was added in 4 mL of blood. The blood is divided up into twelve different 
vials: four of the vials are stored at room temperature, four are stored in the refrigerator 
and four are stored in the freezer. Four vials were used because there were two sets of 50 
ng/mL and 200 ng/mL, one for each of the sample preparation methods. This was done to 
reduce the number of freeze/thaws for the different sample preparation methods since the 
sample would be removed multiple times since two extractions were occurring on the 
same day. These samples are examined over various days (day 0, 2, 4, 7, and 14) to 
determine the stability of the analytes in these samples. These samples are extracted in 
triplicate and analyzed with a new calibration curve. The stability was examined using 
both the liquid-liquid extraction as well as the solid phase extraction method. 
 
3.11 Recovery 
The recovery study was based upon a method that Peters proposed.59 For this 
experiment, ten replicates are required for two different levels of concentration: 50 
ng/mL and 200 ng/mL.  Five of the replicates have the blood spiked with the standards. 
The other five are extracted like negatives. After the extraction process but before the 
heat block evaporation, the samples extracted like negatives are spiked with the 
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appropriate concentrations. All of the samples are added to the heat block and analysis 
proceeds as normal. A fresh calibration curve is created for each analysis as well.  
 
3.12 Analysis/Quantitation 
The peak review, concentration calculations and data analysis were performed 
using Sciex MultiQuantTM 3.0. Any statistical calculations such as mean, standard 
deviation, Fisher test and T-tests were performed using Microsoft Excel for Mac 2011 
(Redmond, WA).  
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4. RESULTS & DISCUSSION 
4.1 UFLC-MS/MS Conditions 
 Two UFLC-MS/MS methods were utilized for this research. The initial method 
was deemed ineffective after a number of runs. Accuracy (or bias) and precision 
experiments were performed for both the liquid-liquid and solid phase extraction methods 
but with inadequate results. The quantitation and peak review for the analytes in 
MultiQuantTM was quite difficult, widely variable and ultimately proved to be inaccurate 
and imprecise. While it is possible that it could have been the extraction methods, the 
solid phase extraction (SPE) method has been used previously for MDMA and MDA and 
it was not determined to be inaccurate or imprecise. With this information, the UFLC-
MS/MS method was examined and optimized with the help of the instrument 
manufacturer. The MS/MS portion was altered from multiple reaction monitoring 
(MRM) to a Scheduled MRM. Table 3 lists the variations between the two methods.  
Table 3. Differences between the two UFLC-MS/MS methods. 
Parameter New  Old 
Scan Type Scheduled MRM MRM 
Duration (min) 6.88 4.971 
Cycle (sec) 0.6 4.0302 
Cycles 668 74 
Target Scan Time (sec) 0.6 
MRM Detection Window (sec) 10 
 
The “new” method resulted in improved quantitation and analyte separation. 
While optimizing the MS/MS method, some transition ions were removed, specifically 
the third transition for the compounds. When moving from the old method to the new 
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method, it was observed that the 6-APB-d5 transitions were not operating properly. These 
were fixed by relabeling the correct transitions as 6-APB-d5A. The old transitions can be 
seen in Table 4 and the new transitions can be seen in Table 5.  
Table 4. Ion transitions used in the old UFLC-MS/MS method. 
Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(msec) 
ID DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
185.076 168.1 150 MDA-d5 IS 1 26 15 10 
185.076 110.1 150 MDA-d5 IS 2 26 33 6 
199.129 165.2 150 MDMA-d5 1 61 19 14 
199.129 135.2 150 MDMA-d5 2 61 29 8 
181.14 133.0 150 5-APB-d5 1 11 29 8 
181.174 164.2 150 6-APB-d5 1 46 15 12 
181.174 133 150 6-APB-d5 2 46 27 8 
194.1 163.2 150 MDMA 1 40 18 12 
194.1 133.1 150 MDMA 2 40 28 10 
176.1 130.8 150 5-APB 1 40 25 10 
176.1 159.1 150 5-APB 2 40 15 12 
178.104 161.2 150 5-APDB 1 41 15 10 
178.104 133.1 150 5-APDB 2 41 29 10 
178.104 77.1 150 5-APDB 3 41 63 12 
190.15 131.2 150 5-MAPB 1 51 29 8 
190.15 90.9 150 5-MAPB 2 51 43 14 
176.078 131.2 150 6-APB 1 46 23 8 
176.078 91.2 150 6-APB 2 46 49 14 
190.123 159.2 150 6-MAPB 1 31 19 14 
190.123 131.1 150 6-MAPB 2 31 29 22 
190.123 91.2 150 6-MAPB 3 31 51 14 
180.083 105.2 150 MDA 1 41 35 8 
180.083 135.2 150 MDA 2 41 29 10 
178.135 161.4 150 6-APDB 1 6 15 28 
178.135 133.1 150 6-APDB 2 6 27 10 
178.135 77.2 150 6-APDB 3 6 57 16 
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Table 5. Ion transitions used in the new UFLC-MS/MS method. 
Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(min) ID 
DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
185.076 168.1 3.02 MDA-d5 IS 1 26 15 10 
185.076 110.1 3.02 MDA-d5 IS 2 26 33 6 
199.129 165.2 3.15 MDMA-d5 1 61 19 14 
199.129 135.2 3.15 MDMA-d5 2 61 29 8 
181.14 133 3.34 5-APB-d5 1 11 29 8 
181.174 133 3.02 6-APB-d5 1 46 27 8 
181.174 136.2 3.02 6-APB-d5 2 46 27 6 
194.1 163.2 3.15 MDMA 1 40 18 12 
194.1 133.1 3.15 MDMA 2 40 28 10 
176.1 130.8 3.34 5-APB 1 40 25 10 
176.1 159.1 3.34 5-APB 2 40 15 12 
178.104 161.2 2.11 5-APDB 1 41 15 10 
178.104 133.1 3.11 5-APDB 2 41 29 10 
190.15 131.2 3.45 5-MAPB 1 51 29 8 
190.15 90.9 3.45 5-MAPB 2 51 43 14 
176.078 131.2 3.35 6-APB 1 46 23 8 
176.078 91.2 3.35 6-APB 2 46 49 14 
190.123 159.2 3.44 6-MAPB 1 31 19 14 
190.123 131.1 3.44 6-MAPB 2 31 29 22 
180.083 105.2 3.02 MDA 1 41 35 8 
180.083 135.2 3.02 MDA 2 41 29 10 
178.135 161.4 3.1 6-APDB 1 6 15 28 
178.135 133.1 3.1 6-APDB 2 6 27 10 
181 133.1 3.34 6-APB-d5A 1 46 27 6 
181.1 136.1 3.34 6-APB-d5A 2 46 27 8 
 
 It is important to note a key difference in the transition ion tables. The units of 
time are different between Table 4 and Table 5. In the old method, the time was related to 
the scanning time in milliseconds. In the new method, the time is the retention time of the 
analyte in minutes. In changing these times, it also changed the overall run time. In the 
initial method the analytical time was 4.971 minutes while the new method is 6.880 
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minutes. While the time increase is not ideal, it has greatly improved the compound 
separation and therefore quantitation results. The increase in time lead to an increase in 
the number of cycles that mass spectrometer can scan and detect the transitions thus 
giving more data points and better quantitation. The increase of scanning time altered the 
peak shape seen in Figure 3.  
 
Figure 3: Chromatograms from old method and new method. Old UFLC-MS/MS 
method produced the peak on left and the new UFLC-MS/MS method produced the peak 
on right.  
 The chromatogram on the left is very sharp and resembles a triangle. The 
chromatogram on the right is more Gaussian in shape. The Gaussian shape is ideal 
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because it indicates that the mass spectrometer is detecting more points compared to the 
triangle shape. This was clarified by Sciex during the process of correcting the UFLC-
MS/MS method.  
 The MS/MS method was not the only aspect that needed to be altered. When 
examining the overall method, it was determined that the initial elution gradient should 
be improved as well. As seen in Figure 4, the elution gradient equilibrated from minute 
4.00 to 5.00 at 30. This in fact should have been the same as the starting point of 5. This 
was corrected and can be seen in Figure 5.  
 
Figure 4: Elution gradient for the old UFLC-MS/MS method.  
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Figure 5: Elution gradient for the new UFLC-MS/MS method.  
 Changing the method midway through the thesis project proved to be difficult. 
Some of the experiments were completed or in progress when the change occurred. This 
required going back to re-work some of the previous experiments, specifcally the 
accuracy and precision, to determine if the new method was in fact better. Some 
experiments ended up using both methods such as the stability. Each section will indicate 
whether the new UFLC-MS/MS method or the old UFLC-MS/MS method was utilized. 
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4.2 Accuracy and Precision 
 Initially, the accuracy and precision experiment was analyzed using the old 
UFLC-MS/MS method. However, as stated in the previous section, there were concerns 
with the quantitation, which confirmed the UFLC-MS/MS method was not optimal and 
imprecise. This was determined using the same method as described below. The accuracy 
and precision experiment was performed again using the new UFLC-MS/MS method. 
The newer method still has room for improvement for both sample preparation methods 
but is more precise than the initial method. 
 Ideally, the bias or accuracy should be + 20%.58 Accuracy is calculated by 
determining the mean for each concentration. The mean for the concentration is 
subtracted by the nominal or actual concentration and then divided by the nominal 
concentration. Since bias is expressed as a percentage, the result is multiplied by 100. In 
the case of this project, this was performed for each analyte at each concentration for 
each sample preparation method. The formula for bias is shown in Figure 6.  
 There are two different precision calculations performed: within-run and between-
run. Within-run precision is examining determining the precision between the replicates 
within the run. It is calculated for each concentration separately for each of the three runs. 
The standard deviation of a single run of samples at a concentration is divided by the 
mean calculated value of a single run of samples. The result of the standard deviation 
divided by mean is multiplied by 100 to obtain the coefficient of variation (% CV).  The 
formula is shown in Figure 6. 
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Between-run precision is examining the precision across all three runs. Between-
run precision is calculated for each concentration similar to the within-run precision. 
Between-run is calculated by dividing the standard deviation of the grand mean of each 
concentration by the grand mean for each concentration and multiplying that result by 
100. For a run, there is a mean for each concentration due to the number of replicates. 
The concentration means for all three runs are then averaged together to obtain the grand 
mean.  The standard deviation of the grand mean is the standard deviation of the 
concentration means across all three runs. The precision should not exceed 20% CV.58 
The formula is shown in Figure 6. 
 
Figure 6: Formulas for accuracy (bias) and precision calculations58. 
All of these calculations were performed using Microsoft Excel. For the precision 
within-run, the largest %CV was reported.  
 
 
 
 
 
 48 
Table 6. Accuracy and precision of the LLE method. Values listed are percentages for 
each concentration (60, 770, 1600 ng/mL). 
  Accuracy Precision Within-Run  Precision Between-Run 
  60 770 1600 60 770 1600 60 770 1600 
5-APB -33.0 -37.8 -36.8 13.6 9.2 15.1 8.3 11.0 4.7 
5-APDB -32.7 -41.7 -47.0 22.6 32.8 32.1 24.2 13.2 23.3 
5-MAPB -40.8 -27.7 -39.0 10.8 28.5 16.8 30.4 12.8 9.8 
6-APB -33.1 -36.5 -37.3 17.8 8.2 12.8 6.8 9.5 7.8 
6-APDB -45.2 -46.5 -40.3 18.9 16.4 26.7 9.4 30.1 25.4 
6-MAPB -39.0 -29.1 -38.5 7.5 27.1 13.4 35.4 11.8 10.2 
MDA -40.2 -35.4 -34.4 26.1 63.8 13.4 12.8 4.7 7.6 
MDMA -42.5 -30.6 -36.3 7.0 8.0 10.8 13.3 19.0 15.1 
 
Table 7. Accuracy and precision of the SPE method. Values listed are percentages for 
each concentration (60, 770, 1600 ng/mL). 
  Accuracy Precision Within-Run Precision Between-Run 
  60 770 1600 60 770 1600 60 770 1600 
5-APB -36.5 -37.8 -40.1 6.0 6.9 4.8 12.4 4.3 6.5 
5-APDB -31.3 -35.3 -37.3 8.8 10.3 17.1 6.1 22.3 22.1 
5-MAPB -38.2 -17.7 -22.0 10.3 11.5 10.5 13.8 15.2 10.6 
6-APB -38.8 -39.6 -40.6 7.8 7.4 8.8 12.6 5.1 10.5 
6-APDB -26.6 -39.5 -43.4 11.5 12.9 17.5 17.2 28.6 22.9 
6-MAPB -42.4 -20.9 -23.6 9.6 11.1 9.2 27.6 13.9 8.9 
MDA -25.6 -37.9 -39.1 7.4 17.5 12.5 12.1 2.2 13.4 
MDMA -45.0 -27.6 -32.6 9.4 6.5 7.8 20.5 16.9 10.8 
 
As seen in Tables 6 and 7, both the sample preparation methods are not optimal. 
Only 5-MAPB at 770 ng/mL extracted using the SPE method is accurate (-17.7%). All of 
the other analytes have accuracy calculations to be greater than -20%.  
 The within-run precision is significantly better than the accuracy. The SPE 
method was precise, with no analytes exceeding 20% CV at any concentration. The 
within-run precision for the LLE method was less precise. While 5-APB, 6-APB, and 
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MDMA were precise for all three concentrations, 5-APDB was imprecise at all 
concentrations and 5-MAPB, 6-APDB, 6-MAPB, MDA were precise at varying 
concentrations (See Table 6).  
 The between-run precision for both extractions was similar. Compounds 5-APDB, 
6-APDB, and 6-MAPB were inaccurate at one or two concentrations. However, for the 
SPE method, MDMA was imprecise at 60 ng/mL. In the LLE method, 5-MAPB was 
inaccurate at 60 ng/mL as well. Overall, the between-run precision is similar between the 
two sample preparation methods.  
 
4.3 Calibration Curve 
 The weighting of the calibration curve or model was primarily determined using 
MultiQuantTM but was confirmed by plotting the area ratio against the concentration in 
Excel. While it is possible to use a quadratic calibration curve, only a linear calibration 
curve was considered. When the calibration curve had no weighting, the calibration curve 
was difficult to utilize for quantitation in MultiQuantTM. This was due to 
heteroscedasticity, which is the variation in calculated concentrations of the calibrators 
compared to the target values. Due to the variation, a weighting factor of 1/x was utilized. 
Considering this, the calibration curves of five different runs were plotted together to 
confirm the model. These calibration curves were graphed by obtaining the area ratio 
between the analyte and the internal standard. The area ratio is the peak area of the 
analyte divided by the peak area of the internal standard. This ratio was plotted against 
the concentration to obtain the calibration model. All of the calibration models reflect the 
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1/x weighting and it was used throughout the rest of the process. Figure 7 and 8 are 
representative calibration models created using Microsoft Excel for 5-APB for the two 
different sample preparation methods. The rest of the models for the other analytes can be 
found in the Appendix B (Figures A - N).  
 
Figure 7: 5-APB LLE Calibration Model. The model is generated from five calibration 
curves from the following five different runs: LLE bias and precision 1, LLE bias and 
precision 2, LLE bias and precision 3, LLE stability day 7 and LLE stability day 14. 
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Figure 8: 5-APB SPE Calibration Model. The model is generated from five calibration 
curves from the following five different runs: SPE bias and precision 1, SPE bias and 
precision 2, SPE bias and precision 3, SPE stability day 7 and SPE stability day 14. 
It should be noted that the calibration model was determined for the new UFLC-
MS/MS method. This is important to note because the quantitation of the old UFLC-
MS/MS method was completed by selecting different internal standards. For example, the 
5-APB deuterated internal standard (5-APB-d5) was run so that it could be used 
alongside 5-APB for quantitation. However, for some runs, 5-APB was better quantitated 
with MDA or 6-APB deuterated internal standard. This variation in internal standard may 
have contributed to the difficultly in quantitation since the same internal standards were 
not consistently used for the same analytes. Rather, it was based on which internal 
standard would give the best quantitation and limit the amount of peak review and 
manual integration required.  
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However, with the use of the new UFLC-MS/MS method, the internal standards 
were correctly associated to their analyte. For those that there were no internal standards 
available, they were associated with MDA or MDMA deuterated internal standard based 
on the similarity in structure. For 5/6-APDB, the MDA deuterated internal standard was 
used and for 5/6-MABP, the MDMA deuterated internal standard was used. While this 
may not have been a contributing factor, it reassured the results could be similar since the 
same internal standards were being applied consistently.  
The MultiQuantTM software generated a calibration curve for each analyte for 
each run. The software would generate the linear equation as well as the coefficient of 
determination (R2). The MultiQuantTM software plotted the calibrators (filled circles) and 
QCs (empty diamonds) as well as the line of best fit (Figure 9). Using the MultiQuantTM 
software, it is also possible to present all of the calibration curves together onto one graph 
as seen in Figure 10. 
 
Figure 9: Calibration curve for MDMA generated by MultiQuantTM Software 3.0. 
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Figure 10: Calibration curve for all analytes for one run generated by 
MultiQuantTM Software 3.0 using the 1/x weighting. 
All of the R2 values for the calibration curves were greater than 0.98 using the 
new UFLC-MS/MS method, regardless of the sample preparation method. The R2 values 
are in two tables located in the Appendix A: LLE R2 values in Table C and SPE R2 values 
in Table D.   
 
4.4 Carryover 
 The carryover between samples was determined by running the double blank after 
the highest calibrator (2000 ng/mL) of the calibration curve. The carryover was 
monitored across five different runs analyzed using the initial UFLC-MS/MS method. 
The average peak areas for the highest calibrator and the double blank were calculated for 
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each analyte. The double blank peak area mean was divided by the highest calibrator 
peak area mean, and then multiplied by 100 to obtain the percentage. The carryover was 
determined to be less than 2% for both extraction methods. All compounds were less than 
0.15% with the exception of 5-APDB, which was 1.56% and 0.50% for LLE and SPE 
respectively. 
Table 8. Carryover for LLE and SPE for all analytes in the method. 
 LLE SPE 
  Ratio Percentage Ratio Percentage 
MDMA  0.0005 0.05 0.0002 0.02 
5-APB  0.0011 0.11 0.0006 0.06 
5-APDB  0.0156 1.56 0.0050 0.50 
5-MAPB  0.0008 0.08 0.0004 0.04 
6-APB  0.0015 0.15 0.0005 0.05 
6-MAPB  0.0006 0.06 0.0004 0.04 
MDA  0.0010 0.10 0.0005 0.05 
6-APDB  0.0025 0.25 0.0011 0.11 
 
 
4.5 Limit of Detection 
 The limit of detection was calculated for each of the analytes in the method for 
both the SPE method as well as the LLE method. The calculation is based on the mean 
and standard deviation of the linear equations for five different runs. These five runs were 
analyzed using the new UFLC-MS/MS method and were the same runs used to determine 
the calibration model. Multiplying the standard deviation of the y-intercept by 3.3, then 
dividing by the mean of the slope is how to calculate the limit of detection. The results 
are displayed in the table below.  
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Table 9. Limit of detection for LLE and SPE. 
  LLE  
(ng/mL) 
SPE  
(ng/mL) 
5-APB 10.44 8.20 
5-APDB 23.73 18.52 
5-MAPB 37.95 33.18 
6-APB 9.98 14.09 
6-APDB 32.57 16.13 
6-MAPB 45.45 40.20 
MDA 27.56 3.75 
MDMA 19.72 23.99 
 
The SPE method has a better limit of detection than the LLE method with the 
exceptions being 6-APB and MDMA. The limit of detection for SPE ranges from 3.75 to 
40.20 ng/mL while the range for the LLE ranges from 9.98 to 45.45 ng/mL depending on 
the compound.  
 
4.6 Limit of Quantitation 
 The limit of quantitation was extracted on runs analyzed using the new UFLC-
MS/MS method. To determine the limit of quantitation, accuracy and precision 
calculations were performed for the lower calibrators 1, 5 and 10 ng/mL. The calculations 
and formulas were the same as those in Figure 6.  
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Table 10. Accuracy and precision for limit of quantitation for LLE. Values reported 
are percentages for each concentration (1, 5, 10 ng/mL). 
Accuracy Precision Within-Run  Precision Between-Run 
  1 5 10 1 5 10 1 5 10 
5-APB 14.2 -16.4 2.7 51.3 10.0 14.8 66.6 6.1 4.2 
5-APDB 214.6 30.0 58.9 77.4 23.3 63.2 30.8 13.7 42.9 
5-MAPB -7.8 93.7 10.6 141.4 99.5 38.6 79.7 71.3 12.5 
6-APB 25.4 -15.7 17.3 141.4 35.6 24.5 85.4 17.7 16.9 
6-APDB 93.1 24.3 20.1 55.8 20.6 35.6 3.5 16.3 31.3 
6-MAPB -9.9 101.3 10.3 141.4 102.4 22.2 78.5 70.0 11.0 
MDA 62.5 -5.4 25.0 70.6 26.0 27.2 63.9 12.4 24.9 
MDMA 5.5 -7.3 -4.5 141.4 9.9 14.6 87.5 4.8 7.2 
  
Table 11. Accuracy and precision for limit of quantitation for SPE. Values reported 
are percentages for each concentration (1, 5, 10 ng/mL). 
Accuracy Precision Within-Run  Precision Between-Run 
  1 5 10 1 5 10 1 5 10 
5-APB -37.1 -26.4 -7.7 141.4 19.3 3.4 47.7 56.9 10.2 
5-APDB -23.9 -48.0 -30.2 141.4 7.4 28.4 39.0 141.4 141.4 
5-MAPB -48.6 -3.8 16.6 141.4 20.8 28.8 30.5 2.7 4.7 
6-APB -51.4 -54.6 -7.4 141.4 141.4 13.8 13.6 128.3 20.9 
6-APDB -3.2 -5.7 17.4 15.4 23.2 4.4 6.9 9.6 1.1 
6-MAPB -49.6 -49.3 -38.0 141.4 21.1 26.8 26.0 141.4 141.4 
MDA -48.0 -52.0 -2.4 141.4 893.7 15.8 19.9 119.6 21.0 
MDMA 890.0 -33.8 -11.7 141.4 92.8 13.1 132.5 33.1 4.4 
  
 Tables 10 and 11 are the results of the calculations.  Similar to the accuracy and 
precision of the method, the accuracy should be + 20% and the precision must not exceed 
20%CV.58 When applying those standards to the limit of quantitation for both sample 
preparation methods, the limit of quantitation lacks accuracy or precision for most of the 
analytes. The LLE method had two compounds (5-APB and MDMA) that were within + 
20% (see Table 10) for all three concentrations but 5-APDB and 6-APDB were outside 
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the + 20% for all three concentrations. The SPE method had one analyte that was within 
the + 20% for all three concentrations (6-APDB) and two compounds that were outside of 
the desired + 20% for all three concentrations (5-APDB and MDMA).  
 The within-run precision reported in the tables was the highest %CV for the 
analytes at that concentration. Overall, the within-run precision exceeded 20% for both 
SPE and LLE. The between-run precision was better than the within-run but with a wide 
variation. The LLE method appeared to be more precise between-runs at a concentration 
of 5 ng/mL and 10 ng/mL while there is a pattern with the SPE between-run precision. 
The SPE was accurate and precise for most analytes at a concentration of 10 ng/mL. The 
SPE method was not as accurate or precise if the analytes were at a concentration lower 
than 10 ng/mL. The limit of detection for the analytes ranged between 9.98 and 45.45 
ng/mL for LLE and 3.75 and 40.20 ng/mL for SPE. Based on the limit of detection, the 
inability to quantify the low concentration levels selected is not possible because the 
levels are well below the limit of detection calculated.  
 
4.7 Stability 
 The stability of the analytes was examined at three different temperatures. The 
temperature ranges of the room temperature (average 19.2°C, range 19 to 20°C), 
refrigerator (average -0.4°C, range 0 to -2°C), and freezer (average -21.4°C, range -17 to 
-24°C) were recorded over the 14-day period. The temperature remained relatively 
constant as seen in Figure 11. The freezer temperature was the only condition that had 
any variation. 
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Figure 11: Temperature Variation During Stability Experiment. 
The stability of the analytes was extracted using both the solid phase and liquid-
liquid sample preparation methods to determine if there was any variability. However, the 
stability study was complicated by the runs completed on days 0, 2, and 4 being analyzed 
using the old UFLC-MS/MS method while the runs completed on days 7 and 14 were 
analyzed using the new UFLC-MS/MS method.  
 The stability of the analytes were quantitated and sorted into various tables (see 
Tables 12 – 17). The tables show the mean plus or minus the standard deviation for each 
analyte on that specific day for that storage condition. Tables 12 – 17 for 50 ng/mL are 
shown below, the 200-ng/mL tables can be found in the Appendix A (Tables E – J). 
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Table 12. 50 ng/mL stored at room temperature extracted using LLE. 
 LLE 
 0 2 4 7 14 
5-APB 43.4 + 5.5 36.1 + 7.5 33.1 + 2.0 31.0 + 2.2 36.0 + 3.6 
5-APDB 33.8 + 4.3 52.6 + 12.6 74.5 + 9.3 42.7 + 5.2 37.6 + 6.9 
5-MAPB 41.8 + 4.4 18.1 + 6.3 27.0 + 2.9 35.9 + 4.0 45.9 + 4.1 
6-APB 24.2 + 4.0 45.9 + 5.5 27.3 + 4.2 31.3 + 2.3 33.8 + 8.3 
6-APDB 32.6 + 3.3 46.1 + 1.8 41.2 + 4.9 44.5 + 5.7 32.9 + 5.4 
6-MAPB 48.7 + 4.3 9.5 + 2.9 37.6 + 1.9 36.4 + 3.6 47.8 + 3.9 
MDA 34.7 + 6.3 39.0 + 1.4 43.2 + 6.8 37.8 + 1.6 37.3 + 3.5 
MDMA 40.3 + 1.1 0.9 + 1.6 36.0 + 2.8 31.7 + 2.8 29.6 + 1.1 
 
Table 13. 50 ng/mL stored at room temperature extracted using SPE. 
  SPE 
  0 2 4 7 14 
5-APB 41.2 + 0.3 31.8 + 1.7 27.8 + 2.2 27.0 + 1.1 26.9 + 2.1 
5-APDB 23.6 + 2.8 35.4 + 11.3 13.2 + 7.9 35.6 + 3.4 30.8 + 0.6 
5-MAPB 44.6 + 3.1 6.7 + 11.7 24.5 + 5.8 27.0 + 0.4 26.5 + 4.1 
6-APB 36.5 + 1.5 25.0 + 27.0 10.2 + 8.6 29.5 + 3.3 27.5 + 1.9 
6-APDB 25.7 + 4.2 24.1 + 13.1 29.7 + 1.5 38.1 + 3.7 34.4 + 2.9 
6-MAPB 46.3 + 3.6 10.0 + 17.3 42.9 + 6.9 27.3 + 0.4 28.1 + 6.7 
MDA 45.0 + 4.4 23.4 + 6.2 34.5 + 1.9 35.9 + 3.0 37.5 + 1.4 
MDMA 41.2 + 2.2 0.6 + 1.0 38.4 + 13.9 25.5 + 2.0 22.9 + 2.7 
 
Table 14. 50 ng/mL stored in refrigerator extracted using LLE. 
LLE 
  0 2 4 7 14 
5-APB 45.4 + 15.5 32.5 + 6.4 37.3 + 0.3 28.0 + 2.8 33.6 + 1.8 
5-APDB 36.2 + 1.3 75.6 + 46.8 48.3 + 15.0 37.9 + 5.6 37.7 + 2.7 
5-MAPB 38.3 + 11.4 12.1 + 8.5 27.4 + 4.4 32.6 + 2.1 42.0 + 3.0 
6-APB 30.1 + 3.8 50.0 + 6.5 39.0 + 11.2 29.9 + 1.3 31.9 + 1.2 
6-APDB 31.1 + 5.4 72.4 + 7.4 48.6 + 9.5 37.7 + 0.4 36.9 + 4.7 
6-MAPB 44.4 + 9.8 1.6 + 1.4 29.3 + 2.8 34.0 + 1.4 44.9 + 4.3 
MDA 32.4 + 4.6 48.9 + 8.4 45.9 + 4.4 36.2 + 2.3 40.6 + 1.6 
MDMA 40.2 + 9.9 1.7 + 2.2 27.3 + 5.3 31.1 + 0.8 28.8 + 1.8 
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Table 15. 50 ng/mL stored in refrigerator extracted using SPE. 
SPE 
  0 2 4 7 14 
5-APB 41.7 + 6.7 30.6 + 1.3 33.9 + 5.9 27.6 + 0.7 24.2 + 1.4 
5-APDB 29.1 + 11.5 28.1 + 1.4 19.9 + 10.2 36.8 + 1.9 35.9 + 3.7 
5-MAPB 40.1 + 2.8 3.2 + 5.5 33.6 + 18.4 30.4 + 2.8 24.6 + 2.4 
6-APB 36.5 + 5.0 18.7 + 15.9 22.0 + 12.4 29.0 + 0.7 25.9 + 3.8 
6-APDB 23.3 + 3.6 20.5 + 13.4 33.5 + 1.0 39.7 + 3.9 38.2 + 2.8 
6-MAPB 45.5 + 4.1 12.5 + 21.6 43.6 + 4.7 30.3 + 1.9 27.2 + 1.1 
MDA 40.3 + 8.0 22.8 + 1.7 37.8 + 6.5 36.5 + 4.7 39.7 + 1.7 
MDMA 40.4 + 3.5 0.6 + 1.0 28.6 + 9.5 25.3 + 0.3 22.2 + 4.9 
 
Table 16. 50 ng/mL stored in freezer extracted using LLE. 
LLE 
  0 2 4 7 14 
5-APB 38.7 + 3.6 35.3 + 2.4 44.4 + 14.5 33.7 + 3.4 35.7 + 3.5 
5-APDB 37.3 + 9.8 50.9 + 10.4 62.8 + 24.2 39.9 + 3.5 32.5 + 4.1 
5-MAPB 44.6 + 10.8 14.5 + 19.5 27.3 + 10.4 31.9 + 1.6 45.1 + 1.7 
6-APB 29.5 + 8.0 39.4 + 26.8 53.0 + 47.8 34.1 + 0.7 32.1 + 3.1 
6-APDB 32.7 + 8.4 50.3 + 15.1 45.6 + 10.9 41.2 + 10.9 36.2 + 3.7 
6-MAPB 45.3 + 6.1 12.6 + 10.9 28.9 + 3.5 32.7 + 1.6 47.2 + 1.7 
MDA 35.1 + 5.7 38.1 + 2.0 48.5 + 3.1  37.7 + 3.4 36.5 + 5.2 
MDMA 39.3 + 4.3 9.9 + 8.6 37.8 + 13.9 30.3 + 1.3 30.5 + 1.3 
 
Table 17. 50 ng/mL stored in freezer extracted using SPE. 
SPE 
  0 2 4 7 14 
5-APB 45.1 + 8.8 34.3 + 4.8 29.0 + 1.7 27.1 + 0.7 28.9 + 2.5 
5-APDB 39.2 + 22.9 39.3 + 7.9 9.2 + 3.2 34.1 + 3.0 35.8 + 4.0 
5-MAPB 42.3 + 4.6 9.0 + 8.8 16.3 + 5.3 30.6 + 4.6 28.9 + 1.6 
6-APB 41.9 + 9.4 33.6 + 21.9 10.8 + 4.0 31.5 + 1.9 30.3 + 1.2  
6-APDB 26.8 + 9.4 24.3 + 15.4 27.7 + 5.1 35.7 + 0.2 36.0 + 0.3 
6-MAPB 45.6 + 4.6 18.1 + 16.9 42.7 + 9.6 30.5 + 5.3 29.6 + 1.4 
MDA 41.0 + 9.8 23.7 + 2.1 39.9 + 4.7 38.5 + 1.4 38.9 + 0.8 
MDMA 41.8 + 5.1 0.0 + 0.0 39.0 + 9.6 27.7 + 4.1 23.8 + 1.0 
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Figure 12: 5-APB LLE Stability (50 ng/mL). 
 
Figure 13: 5-APB SPE Stability (50 ng/mL). 
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Figure 14: 5-APB LLE Stability (200 ng/mL). 
 
Figure 15: 5-APB SPE Stability (200 ng/mL). 
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Figures 12 through 15 show the stability for 5-APB at both concentrations using 
both SPE and LLE. The other analyte stability figures can be found in Appendix B 
(Figures O – AP). As seen in Figures 12 through 15, there is a general trend showing the 
decrease in concentration with some variation between days 0 and 4. This trend does not 
seem dependent on storage conditions. Between day 7 and day 14, a majority of the 
analytes indicates constancy or limited degradation. The variation between days 0 
through 4 can be attributed to the detection and quantitation problems with the old 
UFLC-MS/MS method. The large decreases between the day 0 and day 7 as seen in some 
analytes may have been due to the usage of the old UFLC-MS/MS method. However, it 
cannot be ruled out that since the analytes were all stored together, that there is a possibly 
of the degradation resulting in structures that fragment similar to other analytes in the 
method causing an increase in the concentration. The only way to determine this would 
be to perform the stability study entirely using the new UFLC-MS/MS method as well as 
performing a stability study for each analyte separately. The separation of the analytes 
would allow for the detection of degradation products that have the potential to be similar 
to other analytes in the method. 
 
4.8 Recovery 
 The recovery capabilities of the LLE and SPE methods were examined. The 
recovery was determined by examining the peak areas of those with the drug standards 
added before (pre-spiked) to those added after (post-spiked) extraction. The recovery is 
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calculated by ratio of the pre-spiked divided by the post-spiked samples, multiplied by 
100. The calculations can be found in Appendix A in Tables K and L.  
  The highest percent recovery for LLE at 50 ng/mL was 6-MAPB with 45.9% 
recovery. For 200 ng/mL, the LLE recovery range was between 44.9% and 68.7%. The 
SPE method was capable of recovering the compounds with greater than 80% for both 50 
and 200 ng/mL. The SPE method was determined to have a greater percent recovery 
overall compared to the LLE. The difference in recovery may be attributed to the fact that 
the LLE method was not designed for MDMA or amphetamines. If another method had 
been utilized or if there was time to develop another LLE method, the recovery may have 
been improved.  
Table 18. Recovery percentages for LLE and SPE methods at 50 ng/mL and 200 
ng/mL concentrations. 
  LLE SPE  
  50 200 50 200 
5-APB 27.4 45.4 93.9 83.0 
5-APDB 28.0 47.5 89.7 90.7 
5-MAPB 45.7 61.7 92.0 85.3 
6-APB 28.3 44.9 92.2 83.5 
6-APDB 22.6 50.1 89.2 82.2 
6-MAPB 45.9 62.7 93.5 82.0 
MDA 25.5 59.6 88.6 84.7 
MDMA 45.4 68.7 91.4 83.3 
 
4.9 Statistical Analysis 
 Despite the alteration of the UFLC-MS/MS method midway through the overall 
experiment, the LLE and SPE were compared to determine which may be better suited 
for the sample preparation method for the benzofury compounds. Since the UFLC-
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MS/MS method combined with the LLE and SPE resulted in issues with accuracy and 
precision, the Fisher test (F-test) was utilized first to determine the variance between the 
two sample preparation methods. The null hypothesis was that the variance for LLE was 
equal to the SPE variance. The alternate hypothesis was that the variances were different. 
The F-test indicated whether or not the variances were equal or unequal. Based on the F-
test, the correct T-test was selected and utilized to appropriately compare the means of 
the SPE and LLE. For those experiments that had equal variances, a homoscedastic t-test 
was used. If they had unequal variances, the heteroscedastic t-test was used. All of 
experiments were compared except the stability since the stability experiment may have 
been complicated by attempting to determine the stability of all of the analytes at once 
and the variation of UFLC method between day 4 and day 7. The results of the 
comparison can be found in the table below (Table 19).  
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Table 19. Statistics for LLE and SPE comparison. 
Statistical Calculations for LLE and SPE Comparison 
Comparing Variances Comparing Means 
[C] Fcalc  Fcritical Result Type of T-Test Tcalc Tcritical Result 
Accuracy 
60 2.16 3.79 Equal  Homoscedastic 0.91 2.14 Equal 
770 1.86 3.79 Equal Homoscedastic 0.95 2.14 Equal 
1600 4.44 3.79 Unequal Heteroscedastic 1.23 2.23 Equal 
Precision 
Within-Run 
60 16.11 3.79 Unequal Heteroscedastic 2.63 2.31 Unequal 
770 25.99 3.79 Unequal Heteroscedastic 2.03 2.31 Equal 
1600 2.91 3.79 Equal Homoscedastic 2.12 2.14 Equal 
Precision 
Between-
Run 
60 2.84 3.79 Equal Homoscedastic 0.51 2.14 Equal 
770 1.49 3.79 Equal Homoscedastic 0.11 2.14 Equal 
1600 1.59 3.79 Equal Homoscedastic 0.07 2.14 Equal 
Recovery 
50 26.72 3.79 Unequal Heteroscedastic 15.8 2.31 Unequal 
200 10.81 3.79 Unequal Heteroscedastic 8.64 2.31 Unequal 
LOD 1.05 3.79 Equal Homoscedastic 0.99 2.11 Equal 
LOQ 
Accuracy 
1 18.91 3.79 Unequal Heteroscedastic 0.24 2.31 Equal 
5 5.39 3.79 Unequal Heteroscedastic 3.26 2.23 Unequal 
10 1.04 3.79 Equal Homoscedastic 2.63 2.14 Unequal 
LOQ 
Precision 
Within-Run 
1 1.11 3.79 Equal Homoscedastic 1.06 2.14 Equal 
5 63.65 3.79 Unequal Heteroscedastic 1.03 2.36 Unequal 
10 2.42 3.79 Equal Homoscedastic 1.98 2.14 Equal 
LOQ 
Precision 
Between-
Run 
1 1.79 3.79 Equal Homoscedastic 1.28 2.14 Equal 
5 4.71 3.79 Equal Homoscedastic 2.26 2.14 Equal 
10 21.29 3.79 Unequal Heteroscedastic 1.1 2.31 Equal 
Carryover 10.56 3.79 Unequal Heteroscedastic 0.96 2.31 Unequal 
 
A two-tailed T-test was used to determine if the two sample preparation methods 
had similar means. When using a T-test for comparison, if the means are equal, then LLE 
and SPE are statistically similar. However, if the means are unequal, then LLE and SPE 
are statistically different. 
For the accuracy, precision between-run, limit of detection, and limit of 
quantitation precision between-run, LLE and SPE have equal means, therefore are 
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statistically similar. However, the two methods are statistically different when it comes to 
recovery and carryover. The precision within-run, limit of quantitation accuracy, and 
limit of quantitation precision within-run are divided between equal and unequal means.  
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5. CONCLUSION 
 
 Benzofury compounds and derivatives pose a serious public health issue like all 
new psychoactive substances. Since the prevalence of these new substances within our 
society is unknown, it is difficult to state how often or common these compounds are 
encountered. Since these drugs could already be in forensic casework, it is important to 
examine possible analytical methods to detect these compounds. 
 Ultra fast liquid chromatography with tandem mass spectrometry (UFLC-
MS/MS) is one of the more sensitive analytical techniques currently available for the 
detection of these compounds. While the transitions may become available in the future, 
currently optimizing the compounds specifically to the instrument to be used for analysis 
is necessary. 
 The benzofury compounds and derivatives can be separated. The Scheduled 
MRM method provided improved quantitation results over the un-Scheduled MRM. The 
Scheduled MRM method in combination with the proper column vastly improved the 
separation of the structural isomers. It is possible to distinguish 5-APB from 6-APB 
which improves the accuracy of reporting these compound in forensic casework. 
Improved reporting may help us to understand the prevalence of specific benzofury 
compounds. 
 With the changing of the UFLC-MS/MS method between day 4 and day 7, it is 
difficult to say how accurate or precise the concentrations are between days 0 and 4 with 
regard to analyte stability. This combined with the fact that the stability was examined 
with all of the analytes together could explain the variation in concentrations between 
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days 0 and 4.  Examining the analytes individually or using a constant method may 
provide additional information.   
Regarding sample preparation, the solid phase extraction (SPE) method was 
deemed more efficient for the extraction of the benzofury compounds and derivatives 
from blood. While it is statistically similar to the liquid-liquid extraction (LLE) method in 
accuracy, precision between runs, limit of detection and limit of quantitation, and 
precision between-run, the SPE has a higher recovery percentage compared to the LLE. 
Also - the SPE resulted in less carryover from the highest calibrator to the double blank. 
The SPE method is designed to extract amphetamines while the LLE was not. While the 
UFLC-MS/MS method combined with the SPE may not have the optimal limit of 
detection or limit of quantitation, improvements can be made without a redesign of the 
LLE method specifically for these analytes. In combination with the statistics, the SPE 
appeared to be faster, allowed for automation and required less hazardous chemicals.  
 If or when the benzofury compounds and derivatives gain in popularity in the 
United States, the current methods of sample preparation for MDMA and MDA should 
suffice for these compounds. Although the compounds will need to be correctly 
optimized with the instrument of choice, this project identified an option for a SPE 
method. The SPE provides better recovery and eliminates carryover both of which may 
pose significant issues when examining trace amounts in biological samples.  
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6. FUTURE DIRECTIONS 
 
 The focus on this project was solely on the benzofury compounds and derivatives. 
This however, ignores the fact that toxicology will not only focus on the parent drug, but 
its metabolites to determine dosing and time since usage. While researchers are 
discovering metabolites of these drugs, the research is new and slowly being published. 
The development of analytical standards including metabolites of these compounds is 
also necessary. Hopefully, in the future, more research can be done to determine major 
metabolites, their half-lives and possible indication of dosages, not only in blood but also 
in other biological matrices. 
This project also focused on the 5 and 6 structural isomers, which may not be the 
only isomers present in “Benzo Fury”. While it has been speculated that 2-APB is most 
likely a byproduct or intermediate of synthesis, research has not discovered if it is an 
active compound. In addition, the 4 and 7 structural isomers have yet to be examined for 
effects and metabolites.  
The thesis project only examined the benzofuran drugs together with MDMA and 
MDA, and not in combination with other drugs. There is always a possibility that the 
benzofury drugs can be used in combination with other NPSs as well as other scheduled 
drugs. While this project focused on the benzofury compounds, there are numerous other 
drugs synthesized every day.  
The UFLC-MS/MS method should be further optimized prior to continuing any 
work related to these compounds and derivatives. While the method worked, it should be 
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adjusted to obtain improved accuracy and a lower limit of quantitation and detection. The 
ion suppression and enhancement as well as interference studies should be examined, 
As stated in the Results and Discussion section, the stability study should be re-
examined entirely. The compounds should be analyzed individually to determine if there 
is a possibility that degradation products fragment in similar patterns to other compounds 
being analyzed. Also, the analytes should be run entirely on the same UFLC-MS/MS 
method.  
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7. APPENDIX A 
 
Table A. Lot numbers for all drug standards and deuterated internal standards. 
Compound Lot Number 
MDA FE071612-02 
MDMA FE043013-02 
5-APB FN012413-04 
6-APB FE020513-01 
5-APDB 0461190-1 
6-APDB 0460895-1 
5-MAPB 0462914-3 
6-MAPB 0461052-5 
MDA-d5 FE012813-02 
MDMA-d5 FE05141301 
5-APB-d5 FE08051302 
6-APB-d5 FE05231403 
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Table B. All transition ions optimized. 
Q1 Mass 
(Da) 
Q3 Mass 
(Da) 
Time 
(msec) 
ID DP 
(volts) 
EP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
185.076 168.1 150 MDA-d5 IS 1 26 10 15 10 
185.076 110.1 150 MDA-d5 IS 2 26 10 33 6 
199.129 165.2 150 MDMA-d5 1 61 10 19 14 
199.129 135.2 150 MDMA-d5 2 61 10 29 8 
181.14 164.2 150 5-APB-d5 1 11 10 15 12 
181.14 133 150 5-APB-d5 2 11 10 29 8 
180.3 163.2 150 MDA 1 36 10 15 12 
180.3 105.2 150 MDA 2 36 10 30 8 
194.1 163.2 150 MDMA 1 40 10 18 12 
194.1 133.1 150 MDMA 2 40 10 28 10 
176.1 130.8 150 5-APB 1 40 10 25 10 
176.1 159.1 150 5-APB 2 40 10 15 12 
178.104 161.2 150 5-APDB 1 41 10 15 10 
178.104 133.1 150 5-APDB 2 41 10 29 10 
178.104 77.1 150 5-APDB 3 41 10 63 12 
190.15 159.1 150 5-MAPB 1 51 10 19 12 
190.15 131.2 150 5-MAPB 2 51 10 29 8 
190.15 90.9 150 5-MAPB 3 51 10 43 14 
176.078 159.1 150 6-APB 1 46 10 13 12 
176.078 131.2 150 6-APB 2 46 10 23 8 
176.078 91.2 150 6-APB 3 46 10 49 14 
190.123 159.2 150 6-MAPB 1 31 10 19 14 
190.123 131.1 150 6-MAPB 2 31 10 29 22 
190.123 91.2 150 6-MAPB 3 31 10 51 14 
180.083 163.3 150 MDA 1 41 10 15 16 
180.083 105.2 150 MDA 2 41 10 35 8 
180.083 135.2 150 MDA 3 41 10 29 10 
181.174 164.2 150 6-APB-d5 1 46 10 15 12 
181.174 133 150 6-APB-d5 2 46 10 27 8 
181.174 136.2 150 6-APB-d5 3 46 10 27 6 
178.135 161.4 150 6-APDB 1 6 10 15 28 
178.135 133.1 150 6-APDB 2 6 10 27 10 
178.135 77.2 150 6-APDB 3 6 10 57 16 
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Table C. Coefficient of determination for LLE runs using the new UFLC-MS/MS method. 
  BP 1 BP 2 BP 3 Recovery Day 0 Day 2 Day 4 Day 7 Day 14 
MDMA 0.99465 0.99764 0.99689 0.99692 0.99271 0.98561 0.98907 0.99741 0.9939 
5-APB 0.99746 0.99795 0.99188 0.99287 0.99236 0.9911 0.99943 0.98928 0.99017 
5-APDB 0.9978 0.99626 0.99367 0.99643 0.99033 0.99788 0.99577 0.99905 0.9921 
5-MAPB 0.99499 0.99843 0.99457 0.99535 0.99493 0.9911 0.99897 0.99748 0.99831 
6-APB 0.9978 0.99941 0.99656 0.99453 0.99786 0.99279 0.98758 0.98963 0.99129 
6-MAPB 0.99466 0.99814 0.99522 0.99699 0.99147 0.98331 0.98865 0.99872 0.99778 
MDA 0.99475 0.9987 0.98884 0.99267 0.99837 0.99115 0.99732 0.99016 0.99162 
6-APDB 0.99858 0.99792 0.99874 0.99564 0.99626 0.99075 0.99902 0.99799 0.99051 
 
Table D. Coefficient of determination for SPE runs using the New UFLC-MS/MS method. 
  BP 1 BP 2 BP 3 Recovery Day 0 Day 2 Day 4 Day 7 Day 14 
MDMA 0.99907 0.98784 0.98669 0.98721 0.99886 0.98685 0.99021 0.99435 0.98862 
5-APB 0.9987 0.99779 0.99724 0.99277 0.99376 0.99765 0.99488 0.99717 0.99479 
5-APDB 0.99893 0.99624 0.9878 0.993 0.99824 0.99751 0.98915 0.9989 0.99902 
5-MAPB 0.99911 0.98726 0.98739 0.98506 0.99932 0.98546 0.99011 0.99673 0.99295 
6-APB 0.99769 0.99505 0.99675 0.99374 0.99814 0.99573 0.99262 0.99919 0.9969 
6-MAPB 0.99932 0.98641 0.98907 0.98808 0.9992 0.98641 0.99099 0.99715 0.99502 
MDA 0.99962 0.99688 0.9983 0.99826 0.9939 0.99331 0.99585 0.99942 0.99907 
6-APDB 0.99817 0.99617 0.99663 0.9931 0.99797 0.99423 0.99572 0.99787 0.99859 
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Table E. 200 ng/mL stored at room temperature extracted using LLE. 
LLE 
  0 2 4 7 14 
5-APB 187.6 + 11.2 221.0 + 13.2 170.5 + 15.6 145.4 + 11.8 159.6 + 10.6 
5-APDB 172.4 + 9.3 157.5 + 20.7 190.9 + 37.9 177.2 + 14.0 188.3 + 5.3 
5-MAPB 207.0 + 2.0 151.7 + 28.5 184.6 + 55.0 170.5 + 15.5 202.1 + 10.4 
6-APB 182.4 + 23.6 149.4 + 117.8 155.1 + 15.3 163.3 + 15.3 159.9 + 5.1 
6-APDB 175.2 + 8.6 208.0 + 59.3 143.6 + 22.3 162.3 + 19.0 158.9 + 15.0 
6-MAPB 217.5 + 24.1 193.3 + 63.6 222.1 + 21.7 171.0 + 2.2 201.3 + 7.7 
MDA 194.2 + 7.1 210.2 + 60.7 160.8 + 21.2 157.7 + 12.5 162.3 + 24.6 
MDMA 190.1 + 8.1 235.4 + 72.9 238.9 + 80.4 159.0 + 5.9 172.1 + 5.3 
 
Table F. 200 ng/mL stored at room temperature extracted using SPE. 
200 R  SPE 
  0 2 4 7 14 
5-APB 210.7 + 37.5 169.0 + 27.8 161.1 + 12.9 159.8 + 5.2 145.5 + 2.5 
5-APDB 216.9 + 29.5 226.4 + 71.1 140.0 + 20.2 193.6 + 26.2 174.7 + 11.5 
5-MAPB 206.6 + 8.2 321.2 + 53.2 256.8 + 14.5 197.8 + 5.0 197.3 + 3.8 
6-APB 184.4 + 9.3 258.4 + 134.4 152.6 + 25.8 153.7 + 4.9 144.8 + 4.3 
6-APDB 212.0 + 20.0 179.9 + 37.6 232.6 + 38.1 190.0 + 11.8 172.0 + 20.7 
6-MAPB 233.8 + 10.5 415.5 + 112.0 353.6 + 39.8 191.1 + 2.9 200.1 + 9.5 
MDA 209.0 + 25.1 194.5 + 13.8 241.4 + 32.3 181.5 + 17.8 174.0 + 10.9 
MDMA 209.4 + 9.8 213.5 + 13.9 259.1 + 18.4 187.1 + 6.7 193.1 + 3.4 
 
Table G. 200 ng/mL stored in refrigerator extracted using LLE. 
  LLE 
  0 2 4 7 14 
5-APB 221.0 + 49.6 198.8 + 10.1 184.1 + 25.1 164.4 + 7.9 191.6 + 7.8 
5-APDB 151.4 + 12.8 149.8 + 23.8 226.4 + 65.3 182.7 + 9.4 176.8 + 7.8 
5-MAPB 237.6 + 60.3 192.6 + 40.2 144.2 + 4.1 170.5 + 15.5 189.9 + 8.7 
6-APB 146.4 + 42.4 201.9 + 99.9 82.1 + 18.6 171.6 + 1.6 180.1 + 9.1 
6-APDB 138.3 + 34.4 219.7 + 46.7 149.3 + 11.1 169.6 + 12.4 187.8 + 3.0 
6-MAPB 247.0 + 50.7 197.8 + 26.7 202.9 + 17.6 170.9 + 12.6 187.7 + 13.6 
MDA 174.1 + 38.7 207.9 + 55.5 169.3 + 4.2 172.8 + 10.9 205.7 + 6.6 
MDMA 219.3 + 18.8 182.7 + 15.8 257.1 + 23.5 184.9 + 2.5 172.2 + 3.8 
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Table H. 200 ng/mL stored in refrigerator extracted using SPE. 
  SPE 
  0 2 4 7 14 
5-APB 210.9 + 23.2 172.7 + 11.7 215.9 + 31.4 176.5 + 5.4 177.9 + 7.8 
5-APDB 194.4 + 6.7 231.5 + 53.1 223.4 + 54.0 206.3 + 8.1 210.1 + 13.1 
5-MAPB 218.5 + 18.5 222.0 + 7.7 310.1 + 40.6 186.6 + 3.2 218.5 + 14.4 
6-APB 183.7 + 17.2 46.2 + 5.6 229.7 + 73.6 166.2 + 7.7 183.2 + 7.9 
6-APDB 196.1 + 14.6 510.3 + 91.7 197.7 + 2.4 202.4 + 6.5 200.5 + 20.2 
6-MAPB 235.4 + 12.8 147.2 + 26.9 320.4 + 39.8 182.0 + 2.0 217.0 + 17.9 
MDA 223.2 + 17.7 138.5 + 16.4 222.6 + 11.7 189.6 + 8.0 198.6 + 19.6 
MDMA 207.1 + 9.9 131.8 + 24.8 210.4 + 22.6 194.9 + 2.7 209.6 + 2.9 
 
Table I. 200 ng/mL stored in freezer extracted using LLE. 
  LLE 
  0 2 4 7 14 
5-APB 187.6 + 15.5 202.2 + 30.9 174.9 + 22.4 163.0 + 10.0 175.0 + 17.1 
5-APDB 140.1 + 6.7 180.3 + 32.4 145.9 + 12.0 173.9 + 15.2 161.5 + 16.8 
5-MAPB 192.5 + 39.7 170.8 + 65.6 141.6 + 41.8 170.6 + 11.7 182.7 + 5.9 
6-APB 133.7 + 14.9 204.2 + 132.6 179.5 + 115.3 166.8 + 10.1 170.6 + 17.3 
6-APDB 147.8 + 9.0 196.3 + 23.3 133.6 + 15.5 156.0 + 9.7 160.7 + 18.6 
6-MAPB 209.4 + 32.5 182.8 + 29.5 158.7 + 19.4 165.0 + 8.9 176.8 + 2.8 
MDA 159.9 + 13.0 192.9 + 7.8 180.6 + 17.3 165.2 + 9.8 181.2 + 19.8 
MDMA 182.0 + 12.4 206.6 + 79.1 193.6 + 59.0 167.3 + 9.5 166.0 + 4.3 
 
Table J. 200 ng/mL stored in freezer extracted using SPE. 
SPE 
  0 2 4 7 14 
5-APB 184.9 + 16.0 162.2 + 16.5 165.0 + 18.9 168.0 + 3.4 160.6 + 6.3 
5-APDB 169.6 + 5.9 167.6 + 25.3 151.9 + 24.9 201.5 + 9.1 172.8 + 22.5 
5-MAPB 197.0 + 11.7 305.5 + 50.2 227.3 + 48.0 189.2 + 1.1 205.7 + 28.3 
6-APB 177.3 + 10.0 154.2 + 93.2 132.4 + 45.2 177.3 + 4.3 179.7 + 5.4 
6-APDB 176.0 + 13.5 298.7 + 62.5 160.4 + 16.1 194.9 + 16.2 167.8 + 22.2 
6-MAPB 217.9 + 1.5 351.0 + 122.7 374.7 + 48.1 187.8 + 10.2 200.4 + 16.0 
MDA 214.5 + 27.4 171.2 + 5.8 183.3 + 45.3 180.3 + 11.3 174.7 + 7.5 
MDMA 182.6 + 6.1 190.5 + 31.0 326.2 + 130.0 187.7 + 8.6 194.2 + 6.9 
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Table K. Recovery calculations for LLE method. 
  Pre-spiked Post-spiked   
Analyte  [c] 
Area 
Mean 
Standard 
Deviation Range 
Area 
Mean 
Standard 
Deviation Range 
Ratio of 
Means % 
5-APB 
  
50 49244 13865.4 28930 - 60850 179700 45734.2 139300 - 254100 0.274 27.4 
200 239280 64312.0 177700 - 345400 526880 183703.1 430100 - 795800 0.454 45.4 
5-APDB 
  
50 84754 22517.9 56060 - 106500 303220 70788.6 237800 - 390100 0.280 28.0 
200 434960 170572.0 315000 - 733600 916380 226426.6 643000 - 1215000 0.475 47.5 
5-MAPB 
  
50 190600 41070.7 133000 - 231000 416800 87844.7 305000 - 550000 0.457 45.7 
200 756200 421320.2 421000 - 1490000 1225000 383845.0 737000 - 1710000 0.617 61.7 
6-APB 
  
50 67866 18575.6 37200 - 80880 239440 62967.7 172900 - 333000 0.283 28.3 
200 311580 88270.1 216300 - 456900 694620 260555.2 390400 - 1092000 0.449 44.9 
6-APDB 
  
50 36212 13105.4 16010 - 48370 159980 37342.4 118200 - 212000 0.226 22.6 
200 228840 91772.5 168500 - 390600 456980 122856.6 316100 - 620300 0.501 50.1 
6-MAPB 
  
50 185660 35271.7 139500 - 220200 404900 89079.7 296200 - 544400 0.459 45.9 
200 757980 432249.6 402400 - 1511000 1208840 362657.0 716700 - 1643000 0.627 62.7 
MDA 
  
50 11541 4078.2 8110 - 18220 45218 9324.1 33410 - 55800 0.255 25.5 
200 75488 28932.8 52220 - 125700 126684 43852.4 65280 - 174000 0.596 59.6 
MDMA 
  
50 143660 34975.2 104400 - 184400 316400 60171.2 228400 - 394300 0.454 45.4 
200 631060 321526.2 372600 - 1193000 919160 254197.1 562000 - 1224000 0.687 68.7 
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Table L. Recovery calculations for SPE method. 
  Pre-spiked Post-spiked   
Analyte [C] 
Area 
Mean 
Standard 
Deviation Range 
Area 
Mean 
Standard 
Deviation Range 
Ratio of 
Means % 
5-APB 
  
50 368960 22867.3 333600 - 388800 392960 45153.9 331600 - 458300 0.939 93.9 
200 1316400 177823.8 1158000 - 1585000 1586000 137222.4 1426000 - 1782000 0.830 83.0 
5-APDB 
  
50 656840 28371.5 617600 - 687700 732360 71659.9 669700 - 847900 0.897 89.7 
200 2377800 308616.6 1990000 - 2757000 2623000 171121.3 2445000 - 2842000 0.907 90.7 
5-MAPB 
  
50 770740 68439.2 672600 - 845800 838040 66184.7 743700 - 915600 0.920 92.0 
200 2750000 260593.6 2703000 - 3053000 3223600 205088.5 2897000 - 3400000 0.853 85.3 
6-APB 
  
50 459140 24943.0 441400 - 501600 497940 32914.6 461000 - 537200 0.922 92.2 
200 1597800 191046.3 1376000 - 1841000 1912600 136480.0 1760000 - 2121000 0.835 83.5 
6-APDB 
  
50 345480 21899.2 314600 - 368400 387320 27381.5 356000 - 418300 0.892 89.2 
200 1203200 145260.8 1008000 - 1397000 1464000 104625.5 1327000 - 1582000 0.822 82.2 
6-MAPB 
  
50 780840 57205.9 697800 - 844700 835160 70362.0 735800 - 912300 0.935 93.5 
200 2722000 197958.3 2505000 - 2989000 3318200 140195.2 3127000 - 3477000 0.820 82.0 
MDA 
  
50 103634 2723.1 99470 - 106500 116920 4427.4 112600 - 123500 0.886 88.6 
200 371740 37822.7 321500 - 416000 439140 35799.6 401100 - 480100 0.847 84.7 
MDMA 
  
50 741960 49232.3 663700 - 780100 811500 94855.5 655200 - 910900 0.914 91.4 
200 2573200 199804.2 2230000 - 2751000 3089400 179761.8 2923000 - 3395000 0.833 83.3 
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8. APPENDIX B 
 
Figure A: MDMA LLE Calibration Model. 
 
 
Figure B: MDMA SPE Calibration Model. 
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Figure C: 5-APDB LLE Calibration Model. 
 
 
Figure D: 5-APDB SPE Calibration Model. 
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Figure E: 5-MAPB LLE Calibration Model. 
 
 
Figure F: 5-MAPB SPE Calibration Model. 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
0 500 1000 1500 2000 2500
A
re
a
 R
a
ti
o
Concentration (ng/mL)
5-MAPB LLE Calibration Model
LLE BP 1 LLE BP 2 LLE BP 3 LLE ST 7 LLE ST 14
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
0 500 1000 1500 2000 2500
A
re
a
 R
a
ti
o
Concentration (ng/mL)
5-MAPB SPE Calibration Model
SPE BP 1 SPE BP 2 SPE BP 3 SPE ST 7 SPE ST 14
  
 
82
 
Figure G: 6-APB LLE Calibration Model. 
 
 
Figure H: 6-APB SPE Calibration Model. 
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Figure I: 6-MAPB LLE Calibration Model. 
 
 
Figure J: 6-MAPB SPE Calibration Model. 
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Figure K: MDA LLE Calibration Model. 
 
 
Figure L: MDA SPE Calibration Model. 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
0 500 1000 1500 2000 2500
A
re
a
 R
a
ti
o
Concentration (ng/mL)
MDA LLE Calibration Model
LLE BP 1 LLE BP 2 LLE BP 3 LLE ST 7 LLE ST 14
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
0 500 1000 1500 2000 2500
A
re
a
 R
a
ti
o
Concentration (ng/mL)
MDA SPE Calibration Model
SPE BP 1 SPE BP 2 SPE BP 3 SPE ST 7 SPE ST 14
  
 
85
 
Figure M: 6-APDB LLE Calibration Model. 
 
 
Figure N: 6-APDB SPE Calibration Model. 
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Figure O: 5-APDB LLE Stability (50 ng/mL). 
 
 
Figure P: 5-MAPB LLE Stability (50 ng/mL). 
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Figure Q: 6-APB LLE Stability (50 ng/mL). 
 
 
Figure R: 6-APDB LLE Stability (50 ng/mL). 
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Figure S: 6-MAPB LLE Stability (50 ng/mL). 
 
 
Figure T: MDA LLE Stability (50 ng/mL). 
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Figure U: MDMA LLE Stability (50 ng/mL). 
 
 
Figure V: 5-APDB SPE Stability (50 ng/mL). 
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Figure W: 5-MAPB SPE Stability (50 ng/mL). 
 
 
Figure X: 6-APB SPE Stability (50 ng/mL). 
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Figure Y: 6-APDB SPE Stability (50 ng/mL). 
 
 
Figure Z: 6-MAPB SPE Stability (50 ng/mL). 
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Figure AA: MDA SPE Stability (50 ng/mL). 
 
 
Figure AB: MDMA SPE Stability (50 ng/mL). 
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Figure AC: 5-APDB LLE Stability (200 ng/mL). 
 
 
Figure AD: 5-MAPB LLE Stability (200 ng/mL). 
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Figure AE: 6-APB LLE Stability (200 ng/mL). 
 
 
Figure AF: 6-APDB LLE Stability (200 ng/mL). 
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Figure AG: 6-MAPB LLE Stability (200 ng/mL). 
 
 
Figure AH: MDA LLE Stability (200 ng/mL). 
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Figure AI: MDMA LLE Stability (200 ng/mL). 
 
 
Figure AJ: 5-APDB SPE Stability (200 ng/mL). 
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Figure AK: 5-MAPB SPE Stability (200 ng/mL). 
 
 
Figure AL: 6-APB SPE Stability (200 ng/mL). 
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Figure AM: 6-APDB SPE Stability (200 ng/mL). 
 
 
Figure AN: 6-MAPB SPE Stability (200 ng/mL). 
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Figure AO: MDA SPE Stability (200 ng/mL). 
 
 
Figure AP: MDMA SPE Stability (200 ng/mL).
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